{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.2-dev",
    "document_metadata": {
      "copyright": "Copyright Â© 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Alzheimer's Disease: Targeting the Cholinergic System",
      "version": "1.0.0",
      "authors": "Sandra Spalek",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "receptors/ferreira-vieira2016.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "1,1-dimethyl-4-phenylpiperazinium iodide",
      "id": "f6a683e1c97873337d3e8873ac2e002d60e709bec9d176f2b04e7e0ef15abd652928fdda1bb91a8103329c55b0f03b623db2b3ef3ee31a9f602c638fae446643"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "2-(4-phenyl-1-piperidinyl)-1-cyclohexanol",
      "id": "784f30a25a8035404bdc40e1901d2ead95aa7cb4a896a4877001a8133c486ffc209977d72c84767e8d00ba12712ffdbdaa5ff88cba49e08ec294aaf6f0a0adcc"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "3',5'-cyclic AMP",
      "id": "e634e1d295920557f5cf0c1b3fd2bf18d082b00fb983d6632b989552d1ba51e14a88952b3abfc55d7ab65f035c7e90d951497cfa11719f0492edab0ddb91813a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetyl-CoA",
      "id": "a5fa305d2e2001d715f893ae6c2d622f7e9190eff20a4c42d6ac7af0177896d9464cdd5304827d22ac2fce8b653837ad54d0a95422b99f8fbf8e348571b0e739"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 42",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium(2+)",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "gamma-aminobutyric acid",
      "id": "9583f9418a889245078b43a5744b3aee37f76bff3bff369f21f4091c2ad475d69415b09ff3b3b7e7aa6014f4e5dab6706477099218ce8a665f6751daba94e6b3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamate(2-)",
      "id": "9749d43ec7dd166b90348b70de96bca3f824fa7c4624aa5f0d82f2dbd2e1d559cccd5b7e74c86268f2e152cea542c1a7c99fc9b98d5d12853d44f9a56b615e4a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "myo-inositol",
      "id": "8e30147d621df97bd65d9a05469574cdb77f6e0ffcd739a2cd3f2df34226380c7343ade60b8b2c463d586373a4d2df216e2c743a9c709a568ab5fdd95472dc76"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "organophosphorus compound",
      "id": "fb2bd16451ccd43d230f62f14b1ce9a26599b77e495c4d140a6d02e7d1723c81ea1f3083f3464a10b696289f7011eb26017f4186abd7821415b2e880b3a6334e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Mecamylamine",
      "id": "f81a5cca79277a3483157d6067c10b7916d6c4e183c85db0a42f5f427ebe2280a46a47f3899a13dfa89025b0f2b6dd3a0b02b3240d27c1c06be3d4a662516041"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Muscarine",
      "id": "cd8810a772826fa19ba15a5cd85ae7c504be5704a846c278af3686e509f6111061dd3723150cc75f9bec9a118f6dd0ca90a0c9cec1f6a7f2b90fc754c281ca05"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetate",
      "id": "d5ded90176d5afa9f66d7ba0409d88511fae64124dd5180c6295d21039a13c0acfa4ca0169c04feb91a4195659923665085980b3745f5473e1b4e88b5c54686f"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "antidote",
      "id": "7ae930003e91de197f2d5b15805449a8ee2b3d9d81c78bdbba6d32598295fbca92a3c428b9c792e4c38eebf565205d4418c5a6e2abfc95c121e34468a0843666"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "atropine",
      "id": "e6e78f2f05d79f22e492e95616d895732bdd6244a2994a505f12cc72171d74cbe0826256e86bbfa87c18e6f15bd53e5765abccaf3c49acc948f5bdac58167bdf"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "choline",
      "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "cystine",
      "id": "9e771036593d5eddff7c598b683d7862a0506aa51edf075654e51497b95a147f688f7576b8285f242ada6d10e1cc63d6c81f645233005ba2fec74d889e90dd07"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "donepezil",
      "id": "e1d832febdffe3cc8c4fa21718e0b21719272a1a10c2945cdd3b36cc6ff66c3ec70289ed1ddc3a7a6b79ca44a4bc0fac6ecb12683fc043cdac26b952f7cf5223"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dopamine",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "doxylamine",
      "id": "5590d4b6c165cc71a80a2df8f9ed51c0d035786a9c8f803ddaab7e826c7afc8fd5838c2128eea66f6235b53aca45333af40b3914d7b7abf739c1fdaed9fe8ffc"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "galanthamine",
      "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "memantine",
      "id": "a6417701f850dae3b77bc52ab06561523bf34757aa461d008c48b9b489cf2293a3fb2bd592ae99ac7d23dd6143614f12df64ef718109abeaf9651954c612bfe7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "neurotransmitter",
      "id": "bece6d10e96b69785dbd4c8bab8cbdcd754ff9a5139cabd93dab71c006f16c4b150a518aa934dc852c07fe26a629610104fdc8695476b406a886a07b935c6ccd"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotine",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "noradrenaline",
      "id": "4553f1e4c5c615e68013cac87f15df1fff14c0afbce0727cddfcb8329488f1dbcb9f1fd9b88f78d222bb7b5cc67d2c05a5e1fad860c45047b0fac2778cb1ffac"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "proton",
      "id": "656f481121cc6acad3e40670e0ce89ddb10a6953ac369b676e1dd716269b4ea0cfb7ea117ab37d4a5e8d4ba20d5f59f165dd50390a12b0d8f40f289184a6d8cb"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "rivastigmine",
      "id": "317d5b18448e148088204c7a7dce78316c0ea8b56c70a7adaffe344826b17688e05873b2746050d29c18ae658658e81a2d775ba56b6f5abf8821f4eaca725064"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "serotonin",
      "id": "8d7ceea95cec905de8941facf48d632e3c509b6ce451f835af1fab5789daacc5bbf8d1bdb7cfd90863a70871a9a9a07b093896248712aa6567895ae8cf3b3502"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "succinylcholine",
      "id": "9be71e5c65ebe878c2ffbe016440990d03335150131fd5176a24e764968a672981f703777d758d3c2f9deb29328aa0a570286a74dd1e55f8c844e0055e0de491"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "tubocurarine",
      "id": "01c474637c37396cf09ff718da02e0251a043b483e26f84f6586065d4c0b50bf21418f8c5b1d4764993a68f120a98d1df2d2bfad03e6e974b7e85ab657214d82"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "xanomeline",
      "id": "2fc0c8095fa7470cf35b39ec64fdafb13d4aacaa5cf5fccb346bad55c7db083afc2172727fe8e5e1b11eedbf583482aa264cc408edc9e39f1d6e3a6ce1771a02"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "cholinergic synapse",
      "id": "4c170e68c3f3b683b948384db96f32d3b0cc1acefca0bc761ee56ad72f1e866862673a07a4755e10af696ed903fb018f1c53dc9cf0a73ede83b8faaa63439b04"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "plasma membrane",
      "id": "c91ba9314a78745ee8bdf730be5f8fba1efe5b19352680209444bba471ba7c43aa52e010a74d94e49d1ab3d264e955ae635de541091819e5314c6ba3f8e43d45"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "synapse",
      "id": "cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta fibrils",
      "id": "67b4c76bd9f06b116883a58eaa40e8453f2fda318ae9313477ebc24c6d04613ea373fdf611fd8a740de5a090826662d88c39f2ab166bca226cc8237cb0c71a1a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta oligomers",
      "id": "a0fc661406161db12bdd89333a13d0ee89b3aa089d5eb16676962cae3efd25d4d3dd6e593dbcaebf5fc0c26f9c8c070a98f2ff0fb94a0d52412c0fa0bf6c5b3b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Excitotoxicity",
      "id": "80f0fe9786f726038f985feb4dc24c6add06927628a431fd67220bcc4eee6f64d44b062beb6925b2e5d96998987c03cbc272ea5e23197ce62e58cf17fa7517b7"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Amyloid Precursor Protein Secretases",
      "id": "e5dba1c4bad02dc976d1f20721664d15bb41a252b81651e0af45702b2bae4eee08a93f702d9aca34394ee6533849b56a6cb30da31d0a3a042b3725a02c4cfb9c"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Amyloid beta-Peptides",
      "id": "3561a0e32ad8cad6085b532574f73a3cce1d90648f557d9658ffd734fa10825a5ee8e45f868eb74a3ea6acb478fc4145667df43b0f1205da1a00ea642995747a"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Basal Nucleus of Meynert",
      "id": "55791b8db49179c5e2f02c74d5056d8d60e4fa71f21e025b774bf9dadb8243c6e0dfbc7537f386152a81f84dd6ed7b3dc4dcd803d10368f0d57611d244dbf792"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Calcium Channels",
      "id": "717197b61b759ef2be3144c29f03429113fd927dd475a37f66ab129f4ec169f72cd116e4d75aed0c7c7dfb71a6702a0e1bfb1155246f50ffff060565ace36ff0"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Chloride Channels",
      "id": "99ce372338919d9555406ae988509f576406c8ff148ca506ed80361d69ab9e73f6de1062d2cacd115298dfc074587a9414591cb275ecec679d8069d49ad6c639"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cholinergic Neurons",
      "id": "475e93ca136a9e7794a0aa5f656e5e5514ae3be3984ee430b1c69e597fa87e955ab73e3aa428c790e154477727ce382f73ecadc9ea6ee58ce4366c0b4ed73765"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cholinesterase Inhibitors",
      "id": "b252d42b2ecbfb68db87f06416ccc08afa0d99fb328e5a261206ea6cfae0f6159ac06185addd43240e53ca82a6e028163b36fa5169bd7f418dcfd205f7ca7269"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Hypothalamo-Hypophyseal System",
      "id": "01d1ec2c85eea238b63790147fad4d79c05a4a74490792466801a098c1a56288f50f3bb027491d0b2fb54977d83355bf5f5ed4ff57a0379dc6a597da0a753507"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Ion Channels",
      "id": "5d18aa69556b0ee1bc6e62c486d2fdb103ab46f8f3efaa335925c2bc8087a311b1ba2062efccc91585dad46ec1ea90f10d46eddcc365e130013be3eb08beff68"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Nerve Growth Factor",
      "id": "e39eee0b24c33d4c98fd121d6d3c6686cd8d8c439f9a6df9b924ff73dac127a4aa68ddb575a9af05c73c61fd741ed0cec55012cc562b7856ea595a47f64e57df"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Potassium Channels",
      "id": "46b1db29da1ded5d0ce08e722461346e513844902c7900bea4921bb49ec48c73b6f0872a558ddee5594d55d007f25271413ad8761215ab8880ce65d0d1faf4a3"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Protein-Tyrosine Kinases",
      "id": "6f56cef42f9cab1b2e659ca27e12c0cf76ec61abb71f938b6663468e344f8192b34800498b115fa669f8054311f47f8cf23b526297843866bda8d8f66ac39e0e"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Quinuclidinyl Benzilate",
      "id": "62c4733f9943b6aaf4024b6dcd7001d8dc832bc1cfedca9a476ef83a788730fad3df469de15f562c1ab09132e4a5664dd27a22feae182fedc04920b92be3ab6d"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, Cholinergic",
      "id": "d3bf8fdebccce142752b9fc8505dbbf0b20681a2282315d7e14f15ef75281690d8bc75e6b66c170ad6f85c246d4cedb6cdc3b4ba719bd4d622c3a1e2a60d96c8"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, G-Protein-Coupled",
      "id": "7fc54d93408c787fd4827f788b4ae387d42fd1211c898ba47b57d8aa21006153f1bf55db595962c866b6cde8754ca2d14f2d0a186101f2b989cef1ab3444ac76"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, N-Methyl-D-Aspartate",
      "id": "bc0c849274509856f0839b39c84ee4c4d06be886e9c4a160c019e566da4f7b7da0f773b5326d9d72ab53f350fa5ff3371b3cf66ae89e844579e4eb6102565963"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, Nicotinic",
      "id": "ab9ab8a42f27ea8b317e817b34a7ed7609808e3ccad71f0ce8685fa7b9e53fd847534ce7483452cc11f2166657f178e8e6804466c34019ef9674372b725b155d"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neurons",
      "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "10013505",
      "id": "ed6952bde5750309170d0b7df493e5f17979a541ce04d231a70ea6221f14953753b68a2d0524f1893d2b32af38c7d75414157a8fd84eab0ca95126a6b59712f4"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "1476756",
      "id": "fac3414862f2ee2342e4301cd75c1f6074a14b16163361e822649de6891909b8c75926396b631290723b5e5c1c6d0cfdcf0333e084c81d1620b42dc705da8123"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "9867750",
      "id": "59ed44f2cee63eb7e58fbc123de1917d6b565856494a777c7cd9bb40f5db3f4ecb6e331c5ceae9e45a38b0150eedc54ba1bded4443bd7fc61b898f75ccc9b8db"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "action potential initiation",
      "id": "6f51801f7e712519f75d8699aeffb6f9ac5ae8a8feba5cf3ba5a31d577139528e758d50531ba27e799f3c68a86e5dc61a998a23ac14848a007b70122a89ddbeb"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "calcium ion import",
      "id": "59aba019a24c9b594bdb11c260e05c8c44271642e0bba57cee0d8344900dd37926650926918af680b9817401f222a60b89e3ee614ca2c800bb8ca4decf5e6d1e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "circadian sleep/wake cycle",
      "id": "6b7726173384f8eb927b7a773d744b2cdfb332c69f6d4ada3109cb6f66b163ed2ee53fe97142ff0cebaf797aa81de111046b936c028e1c0191455e9d03ab9781"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "circadian sleep/wake cycle, REM sleep",
      "id": "994160c96a6d0ac2b178e9fbda9b705b8870dc8ac9b6068100d1cc74a25655738da752866b230c4c34f9e4ff3750c8730949f8c41326959a4bcead720bdfd355"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "excitatory postsynaptic potential",
      "id": "7530abec480fef9088630c7c75659c3319b25c0203b3f1e783da5dad1de92f5a07a2124c9fb223f91468243fc3f14894ac43b624ced9fa8405b9151b240b85e1"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "membrane depolarization",
      "id": "e39ac862551cfbabee553faf7cdf77b10d143e9ff3adb94c30b29266575efc988ceb9f023c9c3092ce7eb4f4f002154cd839d4a358db03ef35e2da80ced957f5"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "regulation of circadian sleep/wake cycle, sleep",
      "id": "a29191da4da82e1a0046154bbcc26bcf4a64a7148e0371eaaf3fa4a632075f318889d4679c4155e4305346972b2fa5ae92be0244fdf7a49fa984f2796328aecc"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "regulation of circadian sleep/wake cycle, wakefulness",
      "id": "69ed7881730254280889a8f4e85ee366a5e1b581f120dcfc29a6ab45b268c0e9bc0877479d22c3a986cda5a050940e28cb156c8f63aff59b62eb76dcbdb3708e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "response to stress",
      "id": "6fa75459766cad2fc6b7a639d1866b76e32fe67fc60da0c4813032337226b441dfdb2ef161f19ab85095fc3aa6a4538d309d2c857d6195f021bbdf91fd6ee683"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "sensory processing",
      "id": "338b23e2a14b6d541045638df25f7aefab6baa1d3f68fd54f38be131d2de6d14b634ded4037568e49da2ef9ddc8e37d835264ba41ed87cee3665b81d932fa042"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, cholinergic",
      "id": "4238cec14ccdcd7b90d308eb0687f5775f5b1ed79362c1d84004721894a52040968a92b357a6bf971a144e903a9b441d8be9ba5ee78e5e039c5f83c167933575"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, dopaminergic",
      "id": "30e4d389cce3682af2cd604d08a33dd5d8aa502d5fda93a9cf7ad8ee4d033ee8e9e72d4fb7082b622fae5d7648457514171c04400da110e5eeee4f6d38b23fd8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, glutamatergic",
      "id": "68a9f5219c953044883133bf5f935c2f9a074b8e719aa33dc0766bba8dd98b92cefd134205b93bd6f586b594e1438d307a554c9771bccd03dc6acf03e09bb82c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cognition",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "learning",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "memory",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neurogenesis",
      "id": "ccb2f3e257c49dabd7cf3eeba8cba8fd30968c1bdc7f9e804ced60fd0924e48804ff5f7011ae262bf7de0c708d68125f16ec1341eb14218ff0a4596f3adeac55"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HBP",
      "name": "Neurodegeneration",
      "id": "8f63d9ba3869712b675d29e11f0c0fb09685ddaec0a3a1584becd70b306380d15de58814844a018655820ca2a6e6eca66b0ec6a21ec2e428e8a52dc13eeff56e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Synaptic Transmission",
      "id": "029ab128c5f88cb19d194601faa91ab7741b2fd933156dd2d47e360ce2f97abea415665dbac7bce169ccbcfd285c1628aacfeb15bb6ed2025876778dcc6b8360"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "1,1-dimethyl-4-phenylpiperazinium iodide",
          "id": "f6a683e1c97873337d3e8873ac2e002d60e709bec9d176f2b04e7e0ef15abd652928fdda1bb91a8103329c55b0f03b623db2b3ef3ee31a9f602c638fae446643"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        }
      ],
      "id": "e51486545f3de9ac22ce959d6e705012e8d7800c37ce71e105cde02b38ed2e4a350e78a99c252643ea58e1e7d8e93a14336386f8486b24f98d05b551585a9c47"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "Muscarine",
          "id": "cd8810a772826fa19ba15a5cd85ae7c504be5704a846c278af3686e509f6111061dd3723150cc75f9bec9a118f6dd0ca90a0c9cec1f6a7f2b90fc754c281ca05"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRM",
          "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba"
        }
      ],
      "id": "06c28f83e19d053cf49d5d2edfe04b9a39540b0dc238dbdf569478e51e780a2e160ccdaf032fde1730b0a2dc43376f2a693a6d8683f4a22924066eebc8c6223e"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "cystine",
          "id": "9e771036593d5eddff7c598b683d7862a0506aa51edf075654e51497b95a147f688f7576b8285f242ada6d10e1cc63d6c81f645233005ba2fec74d889e90dd07"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        }
      ],
      "id": "fc46bbc014ee05128c1feb8156c73043fb2bf6e24547533665c355d2c5d2a6885389f3907b3afc1d140dd51c7ac201e237673612bacbc2a72fb85fe413591c01"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "nicotine",
          "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        }
      ],
      "id": "755001b9784553af9df52f25761d4d597267afe4d5d8fb257e62b5589d2625063ca94672b56cf87dd40ac4cd9104d8fb9c1a9fb3afd996c5e197e651b892512f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "GO",
          "name": "plasma membrane",
          "id": "c91ba9314a78745ee8bdf730be5f8fba1efe5b19352680209444bba471ba7c43aa52e010a74d94e49d1ab3d264e955ae635de541091819e5314c6ba3f8e43d45"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "SLC5A7",
          "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50"
        }
      ],
      "id": "706fba2bf76d9b751c81f031b8eb133cbbd1a5cc8f1f8e12ade6364c11c9c76fb9732c0a4da8de6a6c8eeaf1f85e247cc914f491d2cabf1242ad7a040982938c"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "Amyloid beta-Peptides",
          "id": "3561a0e32ad8cad6085b532574f73a3cce1d90648f557d9658ffd734fa10825a5ee8e45f868eb74a3ea6acb478fc4145667df43b0f1205da1a00ea642995747a"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "ACHE",
          "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"
        }
      ],
      "id": "6535cee244f55a596d042ccb1e31d2a16efe4cc4a26d2601f69a67825f04e443fad11c76e9b32d401d3093a0f97ca8be8e3e95d75418fd54e276d98f239c1ef4"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "APP",
          "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "SLC5A7",
          "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50"
        }
      ],
      "id": "56d9fabb464cfd62e36d26ba24b44c91d2708879a5f6a63f1162f6df19f2096251b34e48d80d3fee7153ed65433acece67da32f1888ec614f9f9289caedba12e"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM1",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
        },
        {
          "function": "Protein",
          "namespace": "INTERPRO",
          "name": "G-protein alpha subunit, group Q",
          "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77"
        }
      ],
      "id": "e243c308f64a88d011e51b5fddb3f44996e850eae75e2d32f95da59937533406389e0ba4a846a4a61c720b09cd864abddfd52ad77feb9879dba2621f337b3a93"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM2",
          "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5"
        },
        {
          "function": "Protein",
          "namespace": "INTERPRO",
          "name": "G-protein alpha subunit, group I",
          "id": "565d5a0ce05389cc28d32063238cc00ce7632812ed30abd3835743988317db88f8b40881c918c9a9216139a14c4a046cb4ee8d4abdd55fa5cc9ed22b77a1075a"
        }
      ],
      "id": "ad9ae3574b94e47fd3f6567a24140fce6be957c6ce11810d604498e44de0c78f86e529407cb37743f9be8b3b681de9e23069ed6955627d501ae650646e14ef0e"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM3",
          "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff"
        },
        {
          "function": "Protein",
          "namespace": "INTERPRO",
          "name": "G-protein alpha subunit, group Q",
          "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77"
        }
      ],
      "id": "0a78f83d6243e9b9a4be2366872e83b3dc0a1f5e458204da1f65a7f75a2cb3aad5260314ffc4657fd15bf5f6c8d28d668118858ecdac370ee7e06cd9f0dd91b2"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM4",
          "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969"
        },
        {
          "function": "Protein",
          "namespace": "INTERPRO",
          "name": "G-protein alpha subunit, group I",
          "id": "565d5a0ce05389cc28d32063238cc00ce7632812ed30abd3835743988317db88f8b40881c918c9a9216139a14c4a046cb4ee8d4abdd55fa5cc9ed22b77a1075a"
        }
      ],
      "id": "ce0ffc3af1310b2587b31cffe6ecfcad04993a678c020277d5c37fa52b4c7b1c8f5890665f317b2dc5b5f87ffb23bdfdb778500f8bb9d5d80f8c922f84ee1861"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM5",
          "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b"
        },
        {
          "function": "Protein",
          "namespace": "INTERPRO",
          "name": "G-protein alpha subunit, group Q",
          "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77"
        }
      ],
      "id": "ac5162ffe856bd72e58478396104e20bf9009049c3acccc74a21e35c8d66523c765ff69052127cb0de833499a7a046c462261ec019ff6c7b3769d334aa36567f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA1",
          "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA1",
          "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB1",
          "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRND",
          "id": "0fc12a3743f6213b0a8c9854f102f96f98b6d4ca5f6b93243215c6be9ef59d1071e4a981dfef35497424c052ed7d381aad79e113dad69e8c322a85d581ef69e9"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNG",
          "id": "fdc2324c7ab13b542120da2e930dae1aa2c84562e3bc9a659ddf97ae7412bf4cd7e8ad8fa72eca411b79eb3b1dc8c21dbdeb575bf3d6015c33aae8e21ca0cdf8"
        }
      ],
      "id": "a4801106db4a49d613771d32ab40c9fe7e47086d34e4c4f6eca41cadd9d4656235993bd7bc595242694e66eb64e2d133c7c231cfd711c04c0c50dc847e2b61b7"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "ADCY",
      "id": "b36d4dc9944654bf1f5e6f33f03dbc76cc83f2880a08df6035e6112f55972272204b89f6c77f04b26ab30a6a47686da040163db4333a0d290c87dea9732b3087"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRM",
      "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRN",
      "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRN",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "bf5da142a83cd1e07c52dee8368d5e6ad3811ae933a6716f57286b022234739d57d038c442ebee5af3d25ed396404c3e0a4d49cfd481a330827a381b92d012de"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PKA",
      "id": "a312e28f30d661eb58c0cc3c07cda6812a6290acaa1b8c513be7a895fe1b15f1feb278ee6095359cd3e44eb43cf1864de0fd70d89d3cbcc5b18361fd31276f17"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PKC",
      "id": "12137fadfdc5eb838cd33edabcf36ac0b775609d7303971d52755e1335928a559973fe26211ce3ac9a8599ee75c77a978b44d1d7114437a922a8911d9016aceb"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PLC",
      "id": "a954cf31d48b6ddffaacdf9ac551464d6edda5fead07120c8d6453a89aab5a325ac1795b97e6993441005e73dd31fed063aa1c7c5b0b2ac77d1783fc8006e68c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ACHE",
      "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHAT",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHAT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "15538f34685d662b2f571a385368a154054df320ba912f0dc2e19cbf3af05b2e0e982a07bf39469dd6efc9c2bd75c8b76b1e58ada9d464ab8ff8c734e6353278"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM1",
      "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM2",
      "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM3",
      "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM4",
      "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM5",
      "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA1",
      "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA10",
      "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA2",
      "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA3",
      "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA5",
      "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA6",
      "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA9",
      "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB1",
      "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB3",
      "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB4",
      "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRND",
      "id": "0fc12a3743f6213b0a8c9854f102f96f98b6d4ca5f6b93243215c6be9ef59d1071e4a981dfef35497424c052ed7d381aad79e113dad69e8c322a85d581ef69e9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNE",
      "id": "be917968e1fe7473af686feb02038ad337b17130e7fb40bbeb5ca267ea2629061419099f77345afa3e5418433df2b5cb560b2d7e2fa3a3d936002d4a84d9580e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNG",
      "id": "fdc2324c7ab13b542120da2e930dae1aa2c84562e3bc9a659ddf97ae7412bf4cd7e8ad8fa72eca411b79eb3b1dc8c21dbdeb575bf3d6015c33aae8e21ca0cdf8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GSK3B",
      "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "hyperphosphorylation"
          }
        }
      ],
      "id": "ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "?"
        }
      ],
      "id": "40a1fcd2e6b4af4d7f275f7ffae5cd34aff043c40297e912ed0e45c5a645d1abe2b717042d39ef0fd11ffa06c96785d31a8c7af123db21c2162d4e6ab59b9729"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC18A3",
      "id": "54407dc029292e71e6aa6d83b76ba173d7a64aded707423b0c2afbe6e4fcdba7a178ba1ded256b115be7cba323d1f3f68060181bc944a73f6d8e08ff3245397d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC18A3",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "d54a1a4a5862c9bd446292e2ab7ba4ada8f68272e18acafeda777aa31694a2a7f31573839ff79b44c902c90cf1f123ce98b995890d4750f44c568560685bd55a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC5A7",
      "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYP",
      "id": "b3e408e89a46312126a4fd54c584f1e2cfb020273dcb194206b6813fd13e28c899a0127c25a8b5a407f76aef8a4ea42f4f74375f5e67831de6129644f3336550"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "G-protein alpha subunit, group I",
      "id": "565d5a0ce05389cc28d32063238cc00ce7632812ed30abd3835743988317db88f8b40881c918c9a9216139a14c4a046cb4ee8d4abdd55fa5cc9ed22b77a1075a"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "G-protein alpha subunit, group Q",
      "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "App",
      "id": "78d5e866274e31ff2b09ef6663cb084c62dad139135478daf1645a32988a8214b14330f44be626991077159244c9e35920dcc0025af376746275c215fceafca6"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "App",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "?"
        }
      ],
      "id": "46ac7e8068b43e3b0e5cf5fa539ff95e6608c883c30f4262372ad44d40949680df0fdc8e6115117e8756273e2906cbc0bb391ea60bdd80210c61e08b26d8130c"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Chrm4",
      "id": "c5078486b54ee1c2b9f11e99715457719771e8c62d17d9b9357b7b0bb3928f9f14c5c1c4267f7a2c20cf42c7b2eca175d6b082a34a3a2b614fdb25a7c8506301"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Slc18a3",
      "id": "63dd8e697245b42342d6a9c653698c9a6339983e6f4d2e1adc767ddec13128239bbd3efff08949718e192759bcd57fd8ddea791c07506d8d56cad490cc496b57"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Slc5a7",
      "id": "6ca22d2522fb264522601483416fdf83e3e4b32ed1963b7e925d113b08567e058de62e2d468885bf59c46b9e0db5c25ec99f7e0ad7b9847f5d26b3bb7db1d2d7"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Amyotrophic Lateral Sclerosis",
      "id": "5e56d7b5172af0ae281c2f920b132d7b2263ae5eff7b0f1c9a22347914d8c169c79314aa7738c7e68cf75fac198de894bff58cb9fd4a0cb95ab434310fa07daa"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Cognitive Dysfunction",
      "id": "bd78fa3131dd9ef6067a5fe3ee8689c946c79d0da1bedb054d1f4400b9ad0d3ae041837faa0fbacee0af5a57a4cd343d11e73fd53fd05269e3558803a56df69c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Down Syndrome",
      "id": "3c70bf952a4a541caab3c832e97814c7d87b5c568cc2225ad985dab51802bf5d41c75c20298514df6338380b564189e309d158ae0b7d7729e949a13e9d0f024c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Huntington Disease",
      "id": "1879e0f73bb6f3f680c5793e5c3b9370792a52545c46d4ee9f41a8ef46edd5ba61400e77effb39bd0d1e7f3de6470e091c5d8e6c5beed8d780456b6740a4406c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Mood Disorders",
      "id": "d95abb5844e33e30167f0730751de5ae4022e50ae8d043f4c70e0f2db1fa8ded1a44d79407f846ac0660fb47b3ca13b24eca088816afc2992ed2ed454c415008"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Neuromuscular Diseases",
      "id": "7345fb9aff22fc85d5dcd2ec44717e63ed6fdc2b7d979ab626303664a5f584154c6f9fbb56a6899f2ec7f9c55a561937cb5d83bb5fc8217622577126c4deef0c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Olivopontocerebellar Atrophies",
      "id": "c16073e6a973231d9adabf34e58694576c97ce0b1e1cf016f42d8b3d92aad43b8fb5c87876c91cdb20087805b305fddf6da77e1cee2dabdc9e533860bc4e91d3"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Parkinson Disease",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Psychomotor Agitation",
      "id": "3fd8c0d077f03e4ccf107386d0cf4b288acc7062b8ad86e7c5deade821d379b76b83683a98ec436a52d22ab2ffa764fd2b5d5fad56f9a485cf5cab429c0b9cf4"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Supranuclear Palsy, Progressive",
      "id": "06432576e845db5beb8ae7a4c0ae23454b691ca1773f3467bbd58f6ce3d484e768e57b6abbc21258bd43941d8ed10874fa0d45b24d91638ed7e42dcb0e5c7dd1"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Apathy",
      "id": "82471956361de9bdd217a79180c879a6c5bff20156a1e5faf43108358b5066aa4d692e888a527701bdbb63a5efdd28ba956f0c84cb0d186e41bd9629eb17dabb"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Attention",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Death",
      "id": "7277084fc3a1b0e377445b9052c02ac77fa754286debbdf8cfb948a489cda1bbfabab27531dc1a81026f92c278772709598e2982fd523d37d8d9b888532f8d63"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Dementia",
      "id": "64388ba3ecebbe4d33fb76bedff9f458276b3ae72f47d401c6852d7f9d7c2abf4b2c4cfb899133f8c6ef9f7eff00a84697a1719fa10fed2e67ec00e97d00ed65"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Depression",
      "id": "1db8d744eac9b5ac408852b1889bb0b09e0054ea091932f1aa44aeeab0ea1b3825912c55c72fb2d25d5848e77d62b1c6a1df2063a2f25ae03e5ca30085922799"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Hallucinations",
      "id": "ad73f79878286e99e48ad8b2ff196bd160666327c138014eae6150c76c71e650c37b2e6e083ba61dfda68dd41a788462fb101c654e6ad160cb434a2076b5df14"
    },
    {
      "function": "Reaction",
      "reactants": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetyl-CoA",
          "id": "a5fa305d2e2001d715f893ae6c2d622f7e9190eff20a4c42d6ac7af0177896d9464cdd5304827d22ac2fce8b653837ad54d0a95422b99f8fbf8e348571b0e739"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "choline",
          "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"
        }
      ],
      "products": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        }
      ],
      "id": "67e4f589cdce9497a0a43da03a8a402f89eb6cbd8d585bdd7e3d9026082992e885b82103d791702e1926577a12111ec9021e85e2923ffe51f46285bfce1b08a6"
    },
    {
      "function": "Reaction",
      "reactants": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        }
      ],
      "products": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetate",
          "id": "d5ded90176d5afa9f66d7ba0409d88511fae64124dd5180c6295d21039a13c0acfa4ca0169c04feb91a4195659923665085980b3745f5473e1b4e88b5c54686f"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "choline",
          "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"
        }
      ],
      "id": "ecc251bc346f68dfb6e1f0399d0b3f1ef4cea53f93d67532489ed66c29c326b854fd1ccf38ddd6923d9a3323e1f475b7590ab54136537a9383c13c6d127254fe"
    }
  ],
  "links": [
    {
      "line": 79,
      "relation": "isA",
      "evidence": "Acetylcholine (ACh) was the first neurotransmitter to be identified",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 24,
      "key": "9f0ed14d4c5c91cee8b4f090c7664db7d3b24960bd4c18712aaf4055a6e1731fdc3858d42bcc33bc2ff072826df1a31d9f03aada3f84925a8f8a9d162d92f507"
    },
    {
      "line": 111,
      "relation": "positiveCorrelation",
      "evidence": "Moreover, published data indicate that ACh is involved in memory",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 75,
      "key": "e25cfa9bd67d4706a412f9e6e272d60d97e0683ffe71c55130723839e9e14606fd41998abccdafb21fb168ebc54c35bef8722db5497659b1f60573a360cc7c23"
    },
    {
      "line": 117,
      "relation": "regulates",
      "evidence": "Further studies have demonstrated that endogenous acetylcholine is important for modulation of acquisition [17], encoding [18], consolidation [19], reconsolidation [20], extinction [21] and retrieval of memory",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 75,
      "key": "47ae7b5bb92b437879c10fdc750a09a2b8e1f03cba515715abc7eae64a957189e9ee761dd002910cb97aac6bee5a4a758c0705cab3ca2429616d1dda67f71e10"
    },
    {
      "line": 390,
      "relation": "association",
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 75,
      "key": "2b2bf5aa3575062f68d559b81f287b26bbee3da14a815995d3801219d750c9f4a69558da3ea1d45944c6fd16237cb14b403d86d71f95b0d59f2dc616981d7225"
    },
    {
      "line": 134,
      "relation": "regulates",
      "evidence": "Stress is another factor that can regulate ACh release in the forebrain and its function on the hypothalamic-pituitaryadrenal (HPA) system can modulate biological and emotional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 46,
      "key": "7853458645cfb4420f660e5db67bb77bf406dd09fd58e02d9123199793014c28607d17adf944af8c6f8cd36a0336d60cca4b7c64878dd92d31fb458100d50772"
    },
    {
      "line": 149,
      "relation": "increases",
      "evidence": "Similarly, nicotine can mimic the ACh effects on the HPA axis by activating nicotinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 55,
      "key": "66a9c8ee361c71d5be75c4c21e41945d4738197b5b786b0f7a8dbf813bd9e8b024e530bd0d477631362861be6e109c60c3c778c6d442a0648a9f544ca992dc52"
    },
    {
      "line": 163,
      "relation": "increases",
      "evidence": "ACh contributes to auditory synaptic transmission by facilitating thalamocortical communication",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 70,
      "key": "61d61e8c67e293d9014985cb3d9dba99d3c29e864488448101e39a5fa981b18a58b925498e316e346d331fb8894a403fa65b00763e0ab296e128bb04340e5500"
    },
    {
      "line": 167,
      "relation": "increases",
      "evidence": "Recent evidences also suggest the involvement of ACh in adult neurogenesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 76,
      "key": "a2df9404adbf0f354e6ee99e29177409283dc676582308c6e72d9f2a63862a0a9c2c9c8d716dd9e5894ad824e6d0f7cc15d7fc93a4b851b100dcb84d963b0f8b"
    },
    {
      "line": 232,
      "relation": "increases",
      "evidence": "When cholinergic neurons are depolarized, ACh is exocytosed from synaptic vesicles and released into the synaptic cleft, where it can activate both muscarinic and nicotinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 93,
      "key": "26adb63ac3418c27e0cd3b2e507082df3bacbe6d818dd780e671d86489bc90037ea9c45698f21464294d0eda2ad86663561861f3a86497986eaf53d1c840c660"
    },
    {
      "line": 233,
      "relation": "increases",
      "evidence": "When cholinergic neurons are depolarized, ACh is exocytosed from synaptic vesicles and released into the synaptic cleft, where it can activate both muscarinic and nicotinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 94,
      "key": "48eb94a0ad9c5daae6713c14e748b9c5453e7ad1cc83c2517e3841f2887214360716da3da8327067fd21c085736d5098ad3b4e1d93c279f8848e83d1e40efbd5"
    },
    {
      "line": 266,
      "relation": "increases",
      "evidence": "Choline that is released by ACh hydrolysis in the synaptic cleft is continuously reuptaken into the presynaptic cholinergic neuron by an active transport system (see Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "subject": {
        "modifier": "Degradation"
      },
      "source": 14,
      "target": 17,
      "key": "f55525078c812f94a08c0c79ca0deace7be9528b25d3f03aff0c746539a830ac6f5078987703ad5382080a56c7b3aa445f9061b728fd0bc24b4208bab6c40c54"
    },
    {
      "line": 378,
      "relation": "regulates",
      "evidence": "Thus, ACh can influence the strength and fidelity of various synapses and modulate overall CNS neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 14,
      "target": 78,
      "key": "2f8ff9bdd22b892a78d8cdd6309f7912c414eba79333dab15a6fa486ce72fd3776a58546e701341535c2eb6033847aac1894d31d98a24487dd0343189a8cf9e2"
    },
    {
      "line": 388,
      "relation": "regulates",
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 72,
      "key": "13999f0c98a3fdb114c7195c101eea09cbc392d5d9348e2b866902f63819e82dbc7a02f6cf8f51eedc46b391408dbcb12f9db4e0c7c9983a250686216744a84b"
    },
    {
      "line": 389,
      "relation": "association",
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 74,
      "key": "80a238d17ea11fc0f7806bc5747c7e7ba93f10041ade1d70b3008ecce00b0ac7c040f774f8195bd01fb01062967e5929de47cee105415723342e06ab97dca9b9"
    },
    {
      "line": 504,
      "relation": "association",
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 14,
      "target": 73,
      "key": "90cfb61b93c255d00c27b722ca7e77ed5344c1498fefa675e67ea9dca12e29166fa042c745291bfe917e6316772c81324fc0fb548ffed059c0b86eefe2205531"
    },
    {
      "line": 84,
      "relation": "regulates",
      "evidence": "Given its widespread distribution in the brain, it is not surprising that cholinergic neurotransmission is responsible for modulating important neural functions",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 70,
      "target": 56,
      "key": "df59649a009037615ca1c4c5cc35b6dc3e71206331d590a72ecd2bc9a4ae4757c34ab8cba92cbc4c7f953d8143179483523724f59a730902fc9f0bbffc47cfe1"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 152,
      "key": "25b66d0d63aeaad7975ae36ac072b4d3f33b98a1d343e27cd3ba3b3eea01f227df67eeb70400bffcfd521c5785141dd2057f64a01e16791f6f323e644e392c94"
    },
    {
      "line": 104,
      "relation": "increases",
      "evidence": "On the other hand, the facilitation of the cholinergic transmission by using the cholinesterase inhibitors can improve attention in humans",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 152,
      "key": "3bc5b67fe412ece7220875359e8c6fe0d013938be8547473f75b6f32b32358ffd6f8d5810971c16fa56d715d93414c29ff1371b488994de6f6f7a5cd0316b42b"
    },
    {
      "line": 509,
      "relation": "increases",
      "evidence": "Disruption of cholinergic inputs to the cortex can impair attention and the use of instructive cues needed for decision-making related to ongoing behavior",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 152,
      "key": "d02338c803594274b25ea37e874e2bd81b3adc9e80220b6b244bfcef52718483de05a127a25bad6f7ec552811ea9a4e23ecadabfd8b897f1a887d836b75c9175"
    },
    {
      "line": 89,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 74,
      "key": "d8858b003255bb9ff4b880b1949d142bf90e076552c165c8a8d2abd00a3df746fa16f37e0845d3d0aee2798ac13a5f85882e6ed130a0c55b2ff331dd3bd67b51"
    },
    {
      "line": 108,
      "relation": "positiveCorrelation",
      "evidence": "It has been demonstrated that the cholinergic system plays a role in the learning process",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 74,
      "key": "3a4ee8042be8ef76378c1df480b121ae9cf3a32e731f69641e58dd3e70c31d0bd17d1cf5fa3992f1abd5906b524bfa44176c831bb2bb34c0d6543a787f2efb33"
    },
    {
      "line": 90,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 75,
      "key": "5f93501f724701e46164b68404979e9b8cbeab2ec4d930fb4ed96910a488dfd4309855f59282cbd184b1e2a1b207bc23073ad077b9ea0856d39d2aecaf42e71b"
    },
    {
      "line": 91,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 68,
      "key": "65a9742a7fc816bd26a42ffe0f0d1668f5b2582986128c06240f4db0c2a864e4401afc0a5b7644afa477ea3ad25ab1892b3b8680a2f248b7a231fb7a07a9284f"
    },
    {
      "line": 92,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 67,
      "key": "9badb89e489a419b481a26cb8fadad1c24360f0543ce193b1c47afe5990bdaa658473eebc127c90277c794f9bdcb7dc17fe55d7f8bae6895dbfe82cdee003b87"
    },
    {
      "line": 93,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 66,
      "key": "140d82ceb51177df296dc95eff2f7db624cd87fc123045ee9ab4d24a5f0c5d314e3db94be99747e2d42c18209feebd4e573f98017198a37b2e9ee358a4a9e313"
    },
    {
      "line": 94,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 69,
      "key": "3150defe0ced5a780ab4695670321f7876d9d03ab5704923ee961241b498a0ff0606ba9fa7ba0f83a035308c9180b4ea8d2811c9083c91ad086a879d4080a7ec"
    },
    {
      "line": 153,
      "relation": "regulates",
      "evidence": "Another important function of the cholinergic system is to regulate the sleep cycle",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 62,
      "key": "068b0b923704ba788e98d0eceb5b9058ca4c2bc20365a0584bcf3d44eb8e7afe66ca4493c90f8a0eaa9a31b5b475b139efa1d0d48c2e3829c5378a3c13111c2a"
    },
    {
      "line": 399,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 73,
      "key": "1eaa3960dad9227e5c2b48c840649407bc784ab419316103d20616dfde475673a8d87538051f1bcadcfaa04ff468329506a63084abe1a4876ac30f49fbf3d14f"
    },
    {
      "line": 400,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 77,
      "key": "c4481843d7980f5c0ad3b3a76068f76b0fee6a04647adde0182a2f2d5448fa25eada2fea25f3ebc002a5989308b7bf25003f8952037ff291620d4aec94f5a609"
    },
    {
      "line": 502,
      "relation": "association",
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 140,
      "key": "59f141070092422173205fe7cddc7daefe5d8e44496eb42905f7e52f64fccb412fa6dad04eee1a7a5bb1edc7096183ac3c80c6664abdf4a9babe1a89af1a7f7b"
    },
    {
      "line": 503,
      "relation": "association",
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 70,
      "target": 154,
      "key": "b6e9b5ac42f59917f8e8b316c18b9f4d4194a0752147105812ed6a035a32673e62dc753a4c994dd100c05a1d6249ae8fa7a61a12a2b3e4af3cf742158dd947e9"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 152,
      "target": 70,
      "key": "3152dd65f5e3d9f23064ecb51e8717ec0f3b4c1c7bcbf2be09a2be9a502519d70144b02a6d2a9077ce1388d06ced609e30ef6010828b8f39707b424a0fa093b7"
    },
    {
      "line": 89,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 74,
      "target": 70,
      "key": "e724f8eacdbd7e1b0271fc836cbabc9cd54ca2d7cc448d3d71f7a339b6495d1c4f637c4bab3e254ecee88432bc4670c05626dff0705bf9aeedb71d3e20ea373f"
    },
    {
      "line": 108,
      "relation": "positiveCorrelation",
      "evidence": "It has been demonstrated that the cholinergic system plays a role in the learning process",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 74,
      "target": 70,
      "key": "e0cb0fc29096e9f3488340879f241f874033634444e166d42abbfa5ba26e384d5b8b75f5981bd9b9665333800dff4fc7dcba8f0386b21fd83e991761b90c68ee"
    },
    {
      "line": 389,
      "relation": "association",
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 74,
      "target": 14,
      "key": "1ba10693dab4d9e3c0a642704b9d0dcc09b9607dcb2fca39a247ef6170961eadbbcffa6bf14079b0b7ef60aa4be7a6b1341640fd91de38162a10e7cafb300d1c"
    },
    {
      "line": 90,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 75,
      "target": 70,
      "key": "f4daed5ce170fa0a5e52c8febcd76651fbeb05c7966224e0e8d4102ac0937b822798375bc573ff57c56642e0ee7e6e53b05552df9beb8e7355e739939e25f5a1"
    },
    {
      "line": 111,
      "relation": "positiveCorrelation",
      "evidence": "Moreover, published data indicate that ACh is involved in memory",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 75,
      "target": 14,
      "key": "a397dba15cd5c6991b5138698336beabe1363171dadf2fe10cd997634c5d0bf9bb14d6756044dedcc50401415b6b6f4bb44f5b592a05f42862fd5db4bfd66560"
    },
    {
      "line": 390,
      "relation": "association",
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 75,
      "target": 14,
      "key": "41c6fea3acc69c110d20b54b243cf068f092b5d16e82c05417c519b23c7a39368104ba22d789630434539a336c6677e7b1a8cd7c251127ed4205cb6a70e5d3cd"
    },
    {
      "line": 124,
      "relation": "positiveCorrelation",
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Nucleus of Meynert": true
        }
      },
      "source": 75,
      "target": 44,
      "key": "1f4011f4ac7c31178d83597e03f17aa0a2da14d5f528fa433006ba4170e021b09df56ceaeaf262853d8ae2ef03e878f9a350e208b6884a6e37c8618c4fdc7858"
    },
    {
      "line": 127,
      "relation": "negativeCorrelation",
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 75,
      "target": 77,
      "key": "791a7c1d8a379a34535f48e66caab372eddd59467a2834251bc1ecda94f1bf152d3e3aa8fdfb8837787981e53aeebf0c18224e6f6a703fe82b09b5b09a1cc99d"
    },
    {
      "line": 568,
      "relation": "association",
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 75,
      "target": 78,
      "key": "846e851871772f84c64f458c97b74b6a7f430b30d852c506a342f61458d49f050ab9aa31accd3d7a938fe5719cc6260a62b67f7aaba838a26837705d3521e771"
    },
    {
      "line": 569,
      "relation": "association",
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 75,
      "target": 132,
      "key": "9a3dcf89877c24df5ec01af99fc8c046de4b866b33dcc8bada7d17847580a3644986c190e959c0f2d0181e49fc4364b800d1154f8b454b7bfd88a216269960c9"
    },
    {
      "line": 91,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 68,
      "target": 70,
      "key": "26982bc6d6696ea95d1dd35923aaf9fd8ff62620d358fa90f93e419c1122a94a921a172dc42f3d3e3a0ccee37474ee3d415a57996b021f73ce4bb6c0ac74ebb7"
    },
    {
      "line": 133,
      "relation": "regulates",
      "evidence": "Stress is another factor that can regulate ACh release in the forebrain and its function on the hypothalamic-pituitaryadrenal (HPA) system can modulate biological and emotional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Basal Forebrain"
          }
        }
      },
      "source": 68,
      "target": 14,
      "key": "e37b44215fdb73d06f2cf96fa75aba2f47fdc3080f883b87482b41b4046c1e4fd9feebe033553b3a4f9fdaaee20b6fb07f7acf6b2271eaefe9bb03e2e60e7e0c"
    },
    {
      "line": 92,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 67,
      "target": 70,
      "key": "2a4b5510d2f7e4e14576c48e8ec9a362c5e0a3965cfd2c707be70cccb521619cf9562e7a49b32300d9ff215c2c8fe38b048157b173ac3efbade91aa5dba1979b"
    },
    {
      "line": 93,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 66,
      "target": 70,
      "key": "512d0cd0e5919515dda3f5bbc5b9323076b024ed14197edb58822e2937d62156f64f52a855bc80dfaeee3478d608f2523d43c5f8f5ad79f23f63e685ea8e3ace"
    },
    {
      "line": 94,
      "relation": "association",
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 69,
      "target": 70,
      "key": "72e6a0d5510aa2bd5cde77eae47d53950fe5fbecd1d0b5486dcbc059750429f0a8afb948e30d415aa9904a816ac13d9f3e270615fe49c22bd72db9a22bc7ca5d"
    },
    {
      "line": 99,
      "relation": "increases",
      "evidence": "Experimental data using non-human primates and rodents have demonstrated that injuries introduced to basal forebrain cholinergic neurons that innervate the cortex lead to attention deficit",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 44,
      "target": 152,
      "key": "871c0814ebfa9eca21a0ff9b726b68b3e88daee4c210eb89a39c817298540cd5cd8d279e7de14211eb8f233a4685b45acab70e6f21566c58bb59f27664dd7d5f"
    },
    {
      "line": 589,
      "relation": "increases",
      "evidence": "All these cholinergic alterations that take place in AD closely correlates with impaired attention and memory observed in patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 44,
      "target": 152,
      "key": "2a05a7ba7ecb244269f65fc6c10d2e168e08ef0d56e9d11581d22002df8eb9115c0c04c32bb77c6b305158dff727ff0385461885e132d7a120cc92a51cc7c2ed"
    },
    {
      "line": 124,
      "relation": "positiveCorrelation",
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Nucleus of Meynert": true
        }
      },
      "source": 44,
      "target": 75,
      "key": "3c15df1091c6e687be4d396e722dcdb638be1ca3915183923a1709a26cd6512973479d9d5b35cb07f8b96cfa5c8938dd87323ecf1c59b806e687e03db0a072bf"
    },
    {
      "line": 590,
      "relation": "increases",
      "evidence": "All these cholinergic alterations that take place in AD closely correlates with impaired attention and memory observed in patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 44,
      "target": 75,
      "key": "56ad18496e76836ef20cc372ecbd431584d0ce6c650deaa1c73f9c621e3067352eaf06d9621931f966c5d3069925b9d2e5ae88f4651356a9ba9d70020e84bd32"
    },
    {
      "line": 159,
      "relation": "increases",
      "evidence": "It has been demonstrated that stimulation of cholinergic neurons in precise regions of the brainstem can promote REM (rapid eye movement) sleep, dose-dependently",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain Stem": true
        }
      },
      "source": 44,
      "target": 63,
      "key": "1eb1ed7519a16128a4abcfffa44fd85faf41168327583925fce82a11218db2788600cbe0f3a7b3ef397f104b89416657590f1dc1eac69654f02ae8150e7fa603"
    },
    {
      "line": 171,
      "relation": "increases",
      "evidence": "ACh synthesis takes place in the cytoplasm of cholinergic neurons",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cytoplasm": true
        }
      },
      "source": 44,
      "target": 14,
      "key": "e3beecb2c466e17e9aebfde3dc46e9fe41c253b911826e210c89173f6be5d151c9f60b9afa1d0934d70e3bf8271c69844de3fb35a6540becd6511cf8061494ea"
    },
    {
      "line": 188,
      "relation": "increases",
      "evidence": "Although cholinergic neurons can synthesize choline, the de novo synthesis contributes only with a very small fraction of the total choline that is needed for ACh synthesis (see Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 44,
      "target": 17,
      "key": "149d40ec848e05688e6bd7f8f7fb7c19e3343be2fc8e562dc3fe0eaea55cc23363a6c4b8fb893e716b22870f1ad7f3401774b9784110374065b3932fc2d7a435"
    },
    {
      "line": 244,
      "relation": "increases",
      "evidence": "Cholinergic neurons secrete AChE into the synaptic cleft, where the enzyme is normally associated with the plasma membrane (see Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Synaptic Vesicles"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "synaptic cleft"
          }
        }
      },
      "source": 44,
      "target": 99,
      "key": "4554a57f070090f0c11c82eedb03926ec48762af246a8fc232e5cfbda2d3560e3b466f618b39783c4c7d9dbae9e30ca7574454917c7f9ac2b457e451227bd919"
    },
    {
      "line": 526,
      "relation": "increases",
      "evidence": "It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 44,
      "target": 71,
      "key": "c11bffcc78b68849a331d0179af3aa826449ec2dae2bb2453239c1a3b6ead54cfc5b1d9934070e131bf28a83948b10b66e8fa6c7b69919e5ffae9e38535dae14"
    },
    {
      "line": 528,
      "relation": "decreases",
      "evidence": "It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 44,
      "target": 151,
      "key": "d47957964fba1c27689814a78d9f954ad704b1e0c7ed38d328476a06181994f353347d84d3e467ae22f72549ed2426908b4142a0c6c845c4b37329d766fe046d"
    },
    {
      "line": 529,
      "relation": "decreases",
      "evidence": "It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 44,
      "target": 155,
      "key": "5c05d30034efa15abec473b7080b07bbbd3763f7fd37ccf56d1da0388e402878bb84909a8f0d96483aa34fdafd3f149032e0028a7d1a80a04a88c13c54a3b6f2"
    },
    {
      "line": 545,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 44,
      "target": 140,
      "key": "54b2ed8fd1c8d1bb071c59edaf822681881697dea91f5ce2b7a1826cf474f2cd23012c21eb283e890dfece364dfbb49ec8ed4ae06fadc143a4022d86016872fb"
    },
    {
      "line": 546,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 44,
      "target": 148,
      "key": "5fffce02f893429643111ebaaf9322acc939213886646b416e2b94e7822d83bc60c0afc4f40786b978d52d4a6c29f4cd04d4c155cf609411bb2c8e0c1284987a"
    },
    {
      "line": 547,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 44,
      "target": 143,
      "key": "7a5976ecd9bbdc9012bf6fc6a15e4d9966ff4c0b9fb263e6dd521cafa1ca1bb1b36a36dc0fc4702aa8f5fb284558fdea14f5af7d782739b498ece328e38f6d4d"
    },
    {
      "line": 548,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 44,
      "target": 141,
      "key": "7097943b85c3e18c23fc2e9a7dd6d56677b1a77f58e4a362c050cf82212dfb73c3076e8a135f4d4fdd860c759c333cde72d170afb022a1c0f5c1e454ffe12a0b"
    },
    {
      "line": 549,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 44,
      "target": 150,
      "key": "7307b285e16a1ecffa2b359547961fda60ea6997c2d9ab21e833f50b4635eb5f795970c9de2405764965af50390a6953fe2ccf504e2b874941fbce82fe89efe7"
    },
    {
      "line": 550,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 44,
      "target": 147,
      "key": "6ceffc1c68ebe0202ed210f1fc291d90541edb758e1580946eeaf5d5dea42cb64a34d078eefeecf0103eb885d958680c1877a89ebdf55ae183bb11baecd09618"
    },
    {
      "line": 660,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 44,
      "target": 103,
      "key": "c63cc22036b5dc83ba04b3c2b844d3969baa09cfc1dc5e5ffa521962b292ca0cf0a54e78a6570b8a2c4523d2de24f96a093df33ba30fc4583e629bfd997b5d98"
    },
    {
      "line": 127,
      "relation": "negativeCorrelation",
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 77,
      "target": 75,
      "key": "635e03d1c0adf3d4d4b568b58ad54da286b2582f869a42fec0e67e5d0194c26513fa1dc7b9076d38af3bacee489b7188f0397a82c34766bf06e92440aaf120b9"
    },
    {
      "line": 398,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 77,
      "target": 72,
      "key": "befc6e793333eb7ebe8ebc3f61a16e1823dae2b16816e36fa696d867c0cf870da2dbff6f94228bf6df521b57540557b6449eee7d21587729d33afe543263d2e8"
    },
    {
      "line": 400,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 77,
      "target": 70,
      "key": "70731a14bea3003fb5304200c09f8317d6e2a256be0f9faf641fc74b8d5071a07afad1b97397ac24778327be60b31cd0b3bc6b108cfdb653a03a33be30a43ff0"
    },
    {
      "line": 142,
      "relation": "increases",
      "evidence": "In a work that evaluated the function of the cholinergic system in mediating the response to stress it was found that treatment of rats with the antagonist of the nicotinic receptor, mecamylamine, attenuates the activation of the HPA axis in response to a stressor agent",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 55,
      "target": 46,
      "key": "b89820c0ce369e630173d1e6902026bf160d8967531bd7c000ce58ae9d48d920923f2ff35c5f4406756ca2d1e00e6002950207c62a5bb77d95702147249fda63"
    },
    {
      "line": 350,
      "relation": "increases",
      "evidence": "In the peripheral nervous system, activation of nicotinic receptors leads to rapid synaptic transmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Peripheral Nervous System": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 55,
      "target": 78,
      "key": "ef215782f42a54a1ab219411fc9e43fa392a29c3f29d17d8961d986411e0347c5ae2fa269fb1c442c6881b151989ba00fdc160e37a51b79cabd8892814396dd9"
    },
    {
      "line": 357,
      "relation": "regulates",
      "evidence": "In the CNS, most of the nicotinic receptors are expressed at the presynaptic neuronal membrane and their main role is to regulate the release of neurotransmitters, whereas nicotinic receptors expressed in the peripheral nervous system are mainly post-synaptic",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Membranes": true,
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 55,
      "target": 24,
      "key": "71c2d6f7e83db65405bd4405e11fd2b14149f8f088798a07f3c820e1a989c86d942da19b20bbccc81e956c28e91d719e87451c43ff2f25d5da9f9e0b26121548"
    },
    {
      "line": 365,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Membranes": true,
          "Neurons": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "synapse"
          }
        }
      },
      "source": 55,
      "target": 6,
      "key": "20085b084c79b6d8bccb96290825014e28b91044932c330f1ae2f915b6d1392ae704f2d69d10f1eb7a88f7db656f14d02233e8feed6766f32945cd104ad450c4"
    },
    {
      "line": 702,
      "relation": "increases",
      "evidence": "However, further studies have demonstrated that nicotinic receptor activation can lead to an increase in AÎ²-mediated tau phosphorylation",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 55,
      "target": 127,
      "key": "cf9ed63847a7e2cee5766e18ac202f917c844346552ea0b906774c259d0cb5475a12a3e076633fead30790cb79fb11cd28f2646d5f40383ec2f16f030eddbe9e"
    },
    {
      "line": 143,
      "relation": "decreases",
      "evidence": "In a work that evaluated the function of the cholinergic system in mediating the response to stress it was found that treatment of rats with the antagonist of the nicotinic receptor, mecamylamine, attenuates the activation of the HPA axis in response to a stressor agent",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 11,
      "target": 46,
      "key": "8eda9b64bc4225e5413cf2e46da399e0c839710b1d3e3f682867b937f02b0bd44497a60ecddf8ee2160a4a124dee6f243896ba24f04c19999ad7112b7d57a0d2"
    },
    {
      "line": 148,
      "relation": "increases",
      "evidence": "Similarly, nicotine can mimic the ACh effects on the HPA axis by activating nicotinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 25,
      "target": 55,
      "key": "b3e0f99e4db74865be24e5a9c6a00ceabd20f27f1a936e7c9f1959d604a6df446c4c0fa2e1021668e7c754a25c7bc3522f3616fcf62f6e1b25aec6e383483524"
    },
    {
      "line": 176,
      "relation": "increases",
      "evidence": "The enzyme choline acetyltransferase (ChAT) can synthesize ACh from choline and acetyl-coenzyme A (acetyl-CoA)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 101,
      "target": 157,
      "key": "dc1eb6a9d079f7b68cca182beb17b4beaab6ab29397f3da0f21b733ab0ca55b472238c42985f36003bf3d294733a5c4066ba140e0387660eebfb6677019ab407"
    },
    {
      "relation": "hasVariant",
      "source": 101,
      "target": 102,
      "key": "8ffddbe50788f76436cb12f173efb7d3c2bf92b1d683b765a54c7e6257ff4307d359b532deca5ea31f1da7f5dc2ea7cf9b4edc1c1412ebef1d0b65afa8acae41"
    },
    {
      "line": 554,
      "relation": "negativeCorrelation",
      "evidence": "Moreover, Huntingtonâs disease appears to be associated with decreased ChAT activity",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 101,
      "target": 144,
      "key": "31f6e49404da88dee9caadb74757dd4006349744058d12d57899ca7a6221aebabcbe2e5552593ec2e0e54411364cc51eed115a0f8cd95e4e0d8fa153160366c6"
    },
    {
      "line": 582,
      "relation": "decreases",
      "evidence": "Moreover, it has been demonstrated that ChAT transcription is severely diminished in the remaining cholinergic neurons, which leads to decreased ChAT activity and progression of dementia",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 101,
      "target": 154,
      "key": "be0a6e91bfa775c1f665c4e1fcce5ea560f9fbd6b55fc7e672d69b22161064d9d1864da4cdc4cf368e323d8bfe2e39f7cec2ae678fe32af0409d37c9e9e67516"
    },
    {
      "relation": "hasReactant",
      "source": 157,
      "target": 3,
      "key": "b7a4038970fcc90b38a886ddfc984321f4602a9d4e8ea04407efe739116a29dbbf69e25e6a86466da85ff080d45a78e87339f82d93511faecc27812ee2b24f56"
    },
    {
      "relation": "hasReactant",
      "source": 157,
      "target": 17,
      "key": "0dfcd2b8ee4ab08b59dfb48bdf0dde698ada7e0c914debad30a5142030ab1f39b23aadaee50f095bce2454d169da52c511557f5d3ba368c0926911eb51cd78cf"
    },
    {
      "relation": "hasProduct",
      "source": 157,
      "target": 14,
      "key": "648351a9cc77a8bc75462b2eeb17d36f2a93437a782f4899e188773b46b6e2475a9047a343b6c6d1db928666d1c661358ffa6cf67feaa5a372fe7d53a87ea260"
    },
    {
      "line": 281,
      "relation": "increases",
      "evidence": "CHT1 is mainly found in cholinergic neurons [92-94] and is responsible for supplying choline for the synthesis of ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 17,
      "target": 14,
      "key": "ebbc08ce7e7fb7e9409d83e3cbe24ddd2fa24dc462c130f893f1cf61baf28a6db12d0440b63b518da0c255e4a287e5fa8f0bc43966b25eeb1d9bacf94513761f"
    },
    {
      "line": 182,
      "relation": "increases",
      "evidence": "Following that, the neurotransmitter is transported by the vesicular acetylcholine transporter (VAChT) from the cytosol into synaptic vesicles",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "cytosol"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Synaptic Vesicles"
          }
        }
      },
      "source": 129,
      "target": 14,
      "key": "9134001b743f3ccaa81d0bfef3c985854fd3b39e7278a2b5034e239aa4650818e33b24c2c14893c5e2f5d52a64255ddf531423a90df5666a11a531fe34248bf4"
    },
    {
      "line": 201,
      "relation": "increases",
      "evidence": "Each molecule of ACh transported by VAChT is in exchange for two vesicular protons, which leads to the fulfill of synaptic vesicles with the neurotransmitter",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "cytosol"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Synaptic Vesicles"
          }
        }
      },
      "source": 129,
      "target": 14,
      "key": "7334981d78c24f48f20f6ab713d29dd9912b59f09538698f1b67ea79692604802d3844a53f429027809c3a4426346adae0252f291e3a6ea7f942ad94db39dea4"
    },
    {
      "line": 202,
      "relation": "increases",
      "evidence": "Each molecule of ACh transported by VAChT is in exchange for two vesicular protons, which leads to the fulfill of synaptic vesicles with the neurotransmitter",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Synaptic Vesicles"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "cytosol"
          }
        }
      },
      "source": 129,
      "target": 27,
      "key": "91d1a4d1f6fda0dcaf11d9d1b666c8697807dd7c142d4707c8436eb2bf3130414a4284983d5d9d30100198e3622240a48010ab44a152131349ea452e642fe4f2"
    },
    {
      "relation": "hasVariant",
      "source": 129,
      "target": 130,
      "key": "985719f7a52ee222821cb90b9acc9df6b63c22fdce6df4d0ff1afe6fa239eed254dfc8b83c962a98e628ab4b4154b0efd5423069ccf82a46a4c3e8a6bc9c9425"
    },
    {
      "line": 193,
      "relation": "regulates",
      "evidence": "ChAT activity is regulated by neuronal depolarization, influx of Ca2+ and phosphorylation of the enzyme by a wide variety of protein kinases",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 101,
      "key": "14a329be549b8ac4b95be68da9449ffa7cacd1e00d17ce8ec22ea0af14fdd0522c0d6560efff61070eb9dc24eefd97b99b57f9be32df9de49bfe1ca910a12edc"
    },
    {
      "line": 229,
      "relation": "increases",
      "evidence": "When cholinergic neurons are depolarized, ACh is exocytosed from synaptic vesicles and released into the synaptic cleft, where it can activate both muscarinic and nicotinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Synaptic Vesicles"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "synaptic cleft"
          }
        }
      },
      "source": 65,
      "target": 14,
      "key": "306d87b823754fc9eb03f3e07a69b92c915bf524f4d4c1bd21cb23b02aec502d85017c2936223f6f08782977bceb36dfc0bd973e788ba65a7216a46325a3b3bf"
    },
    {
      "line": 307,
      "relation": "increases",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 65,
      "target": 83,
      "key": "422e6ebb48d8346bdb90ca9c2c1c78e8a53f07c9ddec76b6c819e4200c3f08c4f5661735d3161b0a1e115318c58764dffb0c2d00bfd76bd241dd9390b797d480"
    },
    {
      "line": 195,
      "relation": "regulates",
      "evidence": "ChAT activity is regulated by neuronal depolarization, influx of Ca2+ and phosphorylation of the enzyme by a wide variety of protein kinases",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 61,
      "target": 101,
      "key": "8520c30a6242a0b102f8fc74c80f2ec0f0d724ed6d0d1227c7f231408620a81f8283889d28beccd8a5f54710411325499c87c60794763b18dc0ff29e4d1b4dcf"
    },
    {
      "line": 196,
      "relation": "regulates",
      "evidence": "ChAT activity is regulated by neuronal depolarization, influx of Ca2+ and phosphorylation of the enzyme by a wide variety of protein kinases",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 102,
      "target": 101,
      "key": "dc9e1922ae9c04d5c4a1f8e58f555ddaaeb3dbbf11b126446f9b2324eff4b95f631b6314737adfc5663f9e27efddeeaa317f6e11b5141aa030badcccf869219f"
    },
    {
      "line": 206,
      "relation": "decreases",
      "evidence": "The vesicular transporter activity can be blocked by vesamicol, which is a non-competitive inhibitor",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 129,
      "key": "239be61f70b2bce3ed160981d3d62dc3d06c4d9b415b5b6923d77e66ec7cda05613c5bb17a51783612e5e2fbaf8129b16b71c92afaabef77679cdc42a6a3ad17"
    },
    {
      "line": 207,
      "relation": "decreases",
      "evidence": "The vesicular transporter activity can be blocked by vesamicol, which is a non-competitive inhibitor",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "cytosol"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Synaptic Vesicles"
          }
        }
      },
      "source": 1,
      "target": 14,
      "key": "4f4d56c6f354ab9a97cef791eccd1b1bf2485a41cbd22dc13ffcc6579c68745a2071baba651b0de10a84c3876b675b80f9c44180118c0fefca00b100f8206da7"
    },
    {
      "line": 211,
      "relation": "increases",
      "evidence": "Interestingly, PKC can phosphorylate VAChT and regulate its vesicular localization",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 97,
      "target": 130,
      "key": "5bab3c14764b3a3e878a061ff13c17fd8c7a54ad0b7b58b042749ef09f033bdc34ed7a3b78666a8e6c4cd5c7f52573efb971030653fa0dabfa086cf4ad100826"
    },
    {
      "line": 407,
      "relation": "increases",
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 97,
      "target": 95,
      "key": "bf4f4f647f9251f747d6a6f1b5363805c1ad0e4a12bf36c1887c48e3067c25f66366d70e176c5fef0cd47a0bb2d16a0c215b720bcacf54ad840f347e71c584b2"
    },
    {
      "line": 217,
      "relation": "decreases",
      "evidence": "A VAChT knockdown mouse model, expressing about 68% less VAChT protein, shows major neuromuscular deficits",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 138,
      "target": 146,
      "key": "d237dd533aaa3bd931d60190942ffa7aebc471e03b0b5d1f215b5052e69cfc018c43f7be270c4c0ddcfb677530eb7d888fcde7131be5f93db98922ada563e650"
    },
    {
      "line": 221,
      "relation": "increases",
      "evidence": "Furthermore, cognitive impairment can take place even due to a mild decrease in VAChT protein expression (about 45%)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 138,
      "target": 73,
      "key": "40d0a9e0368172f9b9f2532a2c41deffe131652a6ac83998a40a76117b44be553cb8cd71156aa131d2f2c3bd0d611b56e678e034828349cd41bce520a155b394"
    },
    {
      "line": 397,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 73,
      "target": 72,
      "key": "a45c193f42cfae6e5c53ffde7ae3f8c05fb79d7b6d53e5585a690927d1ec7f77c4e5233d197fcfcae6674377743581323e3b0b6769bc7be5e947e1a537a8d113"
    },
    {
      "line": 399,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 73,
      "target": 70,
      "key": "1014c8016be9d6f9ba1572755f1749e5975c39f6836f913ffeaec0895f852ce242bafd8d8be24d2c91f4bae01d53035464ed1c26c74f7268a9d1d2f57dbdd635"
    },
    {
      "line": 504,
      "relation": "association",
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 73,
      "target": 14,
      "key": "427e051845d20aced0ec5eed999cd2aefac70e9abf7c3695a68c3224c2c92cf1ec992558829dace3e12de7e489575c5d82ae85c9575a9af9dfddb1d6fef66040"
    },
    {
      "line": 427,
      "relation": "isA",
      "evidence": "Muscarinic receptors are G protein coupled receptors that are capable of modulating a wide variety of ion channels",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 93,
      "target": 53,
      "key": "1e1b44ab0db08b16149db0f8735ca2306de2730260319b6ddfe010d91ff6d7059eddc82bb65f1034c1f25330093d94e8be11423a7ef4346b9df02c50709cced7"
    },
    {
      "line": 428,
      "relation": "regulates",
      "evidence": "Muscarinic receptors are G protein coupled receptors that are capable of modulating a wide variety of ion channels",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 93,
      "target": 47,
      "key": "f4c29241dd8bba5ba02d2a8def19c0a0654107f77ac36e26ab116ab8bc8e28a074bf616938f3c973a62b53dd44b16346e93aa2835bc095b4179b2a3379348d27"
    },
    {
      "line": 468,
      "relation": "regulates",
      "evidence": "As a consequence, stimulation of ACh muscarinic receptors can promote the opening or closing of Ca2+, K+, or Cl- channels, which might facilitate either depolarization or hyperpolarization, depending on the cell type where these receptors are expressed",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 42,
      "key": "1d15481e700e6445a140fbef03da0b92a4eb888f1d22d55fcb3799287e03c77bdbf98cb5d1bba0411fd3226c732635dfd8055101623ec1bc4619dd0d6ef15c72"
    },
    {
      "line": 469,
      "relation": "regulates",
      "evidence": "As a consequence, stimulation of ACh muscarinic receptors can promote the opening or closing of Ca2+, K+, or Cl- channels, which might facilitate either depolarization or hyperpolarization, depending on the cell type where these receptors are expressed",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 49,
      "key": "2980e74f704e72ffd9818b97b12397b0e0df571cf2e1498e0be2332ec4d7431f46d248f93f1af11fde3f8b0431052aed0ebafa53ff46663d8d4d4650cfc89bd2"
    },
    {
      "line": 475,
      "relation": "decreases",
      "evidence": "Activation of muscarinic receptors can block various types of K+ currents by inhibiting many resting and voltage-gated K+ channels",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 49,
      "key": "bd0099ac3479d1d3711e687c795a35e1523719c658ec01230e4ed94484d2028b7ed202d59d0d9c0a1dfb9cbf2fb199f96199dd14f347075326fc9e9c14104946"
    },
    {
      "line": 470,
      "relation": "regulates",
      "evidence": "As a consequence, stimulation of ACh muscarinic receptors can promote the opening or closing of Ca2+, K+, or Cl- channels, which might facilitate either depolarization or hyperpolarization, depending on the cell type where these receptors are expressed",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 43,
      "key": "b6c71b45ff5cab0f9c35fc3b2822a01fe76f327efb47907279d19fb7aaf238ebdd321ad73c20ed8f964c8d6771222ebafe19382136a12a6b4d089cafddbad0c4"
    },
    {
      "line": 479,
      "relation": "decreases",
      "evidence": "In addition to decreasing K+ currents, muscarinic receptors located at the presynaptic region can also inhibit GABAergic neurotransmission",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 72,
      "key": "44325fef0cde24eb69dde0466c5bb92203712a8d0ac429c35db69152b7ae6c1900145cb57f974156012e91106eca472e7eaadc04f707ba2e555e7c33adc4c328"
    },
    {
      "line": 383,
      "relation": "increases",
      "evidence": "Agonists of nicotinic ACh receptors can improve, while antagonists for the receptor impair, performance in cognitive tasks",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 94,
      "target": 73,
      "key": "49a3a336270a07883355bab9ed7311abb82cca061d95538b19812a194652b125d4c6c73ddc3b8faa6a738c71baaaacdd407caa4cd0348ef6ef9764990b7026f1"
    },
    {
      "line": 401,
      "relation": "decreases",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 94,
      "target": 77,
      "key": "51b0ecb7b5bc5b0eb923adfd1d260bcfcd7eb859d0018f0c1067fc2597f58b7fa635c9851cb731ef05b9d01bf7a94316ee6ea8459ae0506ba6700b72e0c4b48b"
    },
    {
      "relation": "hasVariant",
      "source": 94,
      "target": 95,
      "key": "ec251192651c9563821f6298d2c0070c05bd62009f6aad9b68b808d708b03be44403e3b07acc8008085c782febff65bb11a20e33dfb31b4fc646806c059397e4"
    },
    {
      "line": 239,
      "relation": "decreases",
      "evidence": "ACh present at the synaptic cleft is rapidly inactivated by the enzyme acetylcholinesterase (AChE), releasing choline and acetate",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 99,
      "target": 14,
      "key": "2f1f691980af0304228e471307abce2a70736510d4e3a0417f8ce51cfb89f097072a5819c60173ea7d6c1a128d5e54af6883355ff7bf82f5f1fd9eabbdf6f8d5"
    },
    {
      "line": 240,
      "relation": "increases",
      "evidence": "ACh present at the synaptic cleft is rapidly inactivated by the enzyme acetylcholinesterase (AChE), releasing choline and acetate",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 99,
      "target": 158,
      "key": "f38b9a9d2e6656e022b7795b6b834f37d8bd457b3b6cea90f1caa51ee5b5226cc8ed5ab888f007f298c912c27455de835bac0679a30bf84a780ab4255af76a3b"
    },
    {
      "line": 595,
      "relation": "association",
      "evidence": "Furthermore, some evidences also suggest the involvement of AChE in the pathogenesis of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 99,
      "target": 140,
      "key": "c75a741a50f03c009c7818d7ec805299bff36be8602dee220da75706047fff97d7f81327d961ff9915620693cc74e7252ae53b609322eb22631f5158beef85ea"
    },
    {
      "line": 604,
      "relation": "increases",
      "evidence": "In this work, kinetic analyses revealed that a structural motif in AChE (a hydrophobic sequence of 35 resides peptides) was able to promote amyloid formation and its incorporation into the growing AÎ²-fibrils",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 99,
      "target": 5,
      "key": "3d20202d1373d375074e6b20a8191530eaeba18232aeb0c42d5c82d798f061febeedbca9990557cff98e63c0d19b0c4b75056fe798b83d344110b33a84e5e6e3"
    },
    {
      "relation": "hasReactant",
      "source": 158,
      "target": 14,
      "key": "8fa8aaa5b29aa56c106b1fdb243fed0b0c01276c1a22e7ff74cbcc1e0646ed2edfb7623455745142dcf387afa90a3d9a6963c69614017443f5a2bb5b50e8ce79"
    },
    {
      "relation": "hasProduct",
      "source": 158,
      "target": 13,
      "key": "9f7f1f3543540f275d2f8baa7ab4095849858e13cdd631d7bf04c761bbd3c1d4c2bb9e350c1c84ff2ab1bc004a33aed57a87e2713e5cf867b5cd8d5dad335a34"
    },
    {
      "relation": "hasProduct",
      "source": 158,
      "target": 17,
      "key": "047f68ef276dda59a670e84550acbf50d53018921a51fe8237537d0fb5860e861927eae3563e63a07201c0b33906f4e0c8be4d67f898ddadd52769a225e52082"
    },
    {
      "line": 248,
      "relation": "decreases",
      "evidence": "The organophosphate compounds are irreversible AChE inhibitors that are used as insecticides and nerve gases",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 10,
      "target": 99,
      "key": "a008815f15239b6ce004b16d9153ec6ba51eebfe96c3bcc35cb7bfe0ce7ac0e41d55a0cafcdfa5472ee9721c69aa75611a0a63e729bbdf536bce431309ba6b8b"
    },
    {
      "line": 253,
      "relation": "increases",
      "evidence": "Thus, antidotes, including doxylamine, can be used to speed enzyme regeneration",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 99,
      "key": "16d76e848888b84db4627db5afdd55c18add1b861728798fd3724615d1c22a068d4b43ffd6ff6598c5e8ada622a36994f0d1c4fbfcb8da5cf664999b987b1181"
    },
    {
      "line": 254,
      "relation": "increases",
      "evidence": "Thus, antidotes, including doxylamine, can be used to speed enzyme regeneration",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 21,
      "target": 99,
      "key": "7f677693bb106ae427e627da5fca1ac32aa18927fd277fcdd7a6d20da156228538f6b3484ae257929b31a6910be95f8d956816895bf659ed4113d425b7dacc94"
    },
    {
      "line": 260,
      "relation": "decreases",
      "evidence": "Moreover, AChE inhibitors that compete for the enzyme site, as succinylcholine, are used as anesthetic adjuvants since these drugs can promote neuromuscular blockage",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 30,
      "target": 99,
      "key": "c85daf6525f1f6ec188260dda035d82718940b5fc754a517bd23a408c624b8caccf979c82e49a668e9413917c0d655a678a217f010296b4c377cbc511239790c"
    },
    {
      "line": 267,
      "relation": "increases",
      "evidence": "Choline that is released by ACh hydrolysis in the synaptic cleft is continuously reuptaken into the presynaptic cholinergic neuron by an active transport system (see Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "synaptic cleft"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Cholinergic Neurons"
          }
        }
      },
      "source": 131,
      "target": 17,
      "key": "61ce9609a81a778d1266a94dc867943b5eae3e82e11d7d9a23bf637a8a6818ec75e2083e523901ca014c47d9ecb36651e8c5d3889ea2bc6708776ad4a8102bd3"
    },
    {
      "line": 275,
      "relation": "increases",
      "evidence": "Two choline transporters have been identified in neurons: a ubiquitous, low-affinity, sodium-independent transporter that can only be inhibited by high concentrations of hemicholinium-3 (HC-3) (Ki of about 50 Î¼M), and a highaffinity, sodium-dependent, HC-3-sensitive (Ki of 10-100 nM) choline transporter (CHT1)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "synaptic cleft"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Cholinergic Neurons"
          }
        }
      },
      "source": 131,
      "target": 17,
      "key": "a5b4b04c26b00b638f593f6b5139f0bb49a05ecd984271c9d0e3ecbead43e00b0c40bf063a60680c7868dacb0f58a5bbaac0fe30db1403e6403e9f824bd15461"
    },
    {
      "line": 280,
      "relation": "increases",
      "evidence": "CHT1 is mainly found in cholinergic neurons [92-94] and is responsible for supplying choline for the synthesis of ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 131,
      "target": 17,
      "key": "9f9bf73f51d0af4963b4ca30875d7fd1271bfe995404bfb8c571d0b99097856ab79fe0471487d9600e95ba54b791dc2e97c087e3ec7ac96c543afc459705cbad"
    },
    {
      "line": 302,
      "relation": "increases",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "synaptic cleft"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Cholinergic Neurons"
          }
        }
      },
      "source": 131,
      "target": 17,
      "key": "3d464bd64965765c1634e53598ba4c6f3b29e564447284e6d8b1412819d4241177ab8a8be6f1168f036bbd90d2d316aff3496d85ec40c88d04d15ba7a19b43d9"
    },
    {
      "line": 303,
      "relation": "increases",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "source": 131,
      "target": 14,
      "key": "d36f2d45445cad123dbbc66f650b078f34c01687f28e47769fb9353f1d8181c2491b22be5158ae98ece8c9f85a7a09922ef63239e74cbbf3b6be980bff466838"
    },
    {
      "line": 288,
      "relation": "decreases",
      "evidence": "Moreover, mice that display a disruption of CHT1 gene expression exhibit symptoms related to ACh deficit and inevitable death within an hour of birth",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 139,
      "target": 153,
      "key": "f5e6150f76b1d848d3f53430edf65c1b96fa0e9fcf6734337451a397ff03ba65724951d00c4fe4855c6a5ed6e2f06684d5db0aa47bdfeba2e2e00e6ba29c8a1b"
    },
    {
      "line": 293,
      "relation": "increases",
      "evidence": "Interestingly, it has been demonstrated that an increase in neuronal firing can lead to an increase in choline uptake and in the synthesis of ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 60,
      "target": 17,
      "key": "e13cb957a6e4969f17ed384222505f1e3d5cd858d5265ee5ca10c34568eff0b14bab1965e89ae0c0fb7d185c990096adea52c827b3e5ca09005bab3d720ad4cc"
    },
    {
      "line": 304,
      "relation": "increases",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "synaptic cleft"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Cholinergic Neurons"
          }
        }
      },
      "source": 60,
      "target": 17,
      "key": "b3bb5e88a1f01b194e29a66fe5bd86be850a9df2d46fff8a7396ac3a3392a20bbb994e0c9dde11a42a289f5a175e638da35bd8ceda6fad2d46f0dc807fd74ee6"
    },
    {
      "line": 294,
      "relation": "increases",
      "evidence": "Interestingly, it has been demonstrated that an increase in neuronal firing can lead to an increase in choline uptake and in the synthesis of ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 60,
      "target": 14,
      "key": "767a9906681da353fe79b7d75deda28df18f86ad6b10ab1dcfa7e24a62d7183d8dba3892e17eef6a25a587eaa216691b7afb1bff18c198da9d80025171ccb098"
    },
    {
      "line": 305,
      "relation": "increases",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "source": 60,
      "target": 14,
      "key": "72cc0cf3e298166d66facdeddacc6ff9ea53667c8ad9e2b4ebed81a8e1da0322c3063124f49fd027d5371ad4ddce57eb12ea3ab957e1332168a2d4eb58d20268"
    },
    {
      "line": 308,
      "relation": "association",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 60,
      "target": 83,
      "key": "cc2aea3fc1cde43ecda64e99b801511ec88f1aee71e6bbadccd12dc971c63a677af7816ab0e3f01e07adc2a1fb298530ab787f124e6b7e2b2b96c293a3540807"
    },
    {
      "relation": "hasComponent",
      "source": 83,
      "target": 34,
      "key": "813c186025ae58007f34955667c0bd3bb1f586537ea2f2913062c25cd9886e554768a21b91e83a6b8114ddd2598f6988952a5a123a8c75a4410bb3e6a6893550"
    },
    {
      "relation": "hasComponent",
      "source": 83,
      "target": 131,
      "key": "7855b7cc046bd9dc1349ad4bb54aff8ff4aec0139debe7189f26decc802e4f4f156038b7b2f387578dd9ac42d815e4e188284b3df667b8b025e881be5dda91d2"
    },
    {
      "line": 308,
      "relation": "association",
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 83,
      "target": 60,
      "key": "df30edc1b19423dcae0e9f6cd45281374af5b846de905bd7aa07109533573881825036653423923bf660e0453241a41ad47bfb12cecbf3b2f7cb39d971cbcff4"
    },
    {
      "line": 313,
      "relation": "increases",
      "evidence": "Importantly, the neurons that form the nucleus basalis of Meynert undergo extensive degeneration in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 140,
      "target": 41,
      "key": "cdeb61c443f8e2156718468455cee31baf1e76f2f0d00116d2a036a78de85d7d933ce727c94815f995d1a438615758de5af8bc31a1ee3419a9ed3cb119910aec"
    },
    {
      "line": 576,
      "relation": "negativeCorrelation",
      "evidence": "The loss of the nucleus basalis cholinergic neurons in AD patients is severe: from about 500,000 in the healthy adult to less than 100,000 in patients displaying advanced AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 140,
      "target": 41,
      "key": "5abdb73f06a887b67dfb0de1b64c1e8108477c4ed4fcd9b1ac9d330a164cb29e41906737f1c6c3811f658ff515580def38df4a050652c7a184f7480dd28b6420"
    },
    {
      "line": 502,
      "relation": "association",
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 140,
      "target": 70,
      "key": "283b97438ba041fcdbfed79bbd0eed1b89aebb129d532fc6cbc50208a508cb887a0e2108771bfb52793f9eb0b14f09e34855dcb69e5005e90eec9e62d3db71e8"
    },
    {
      "line": 518,
      "relation": "positiveCorrelation",
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 140,
      "target": 151,
      "key": "08b48ec6ee3c50a6b9a5eedb92caa7c0f4d752ee6263863984fe5dc36b3f31be0ee5005f53c3aec6a6ca706d68e82a6e9b1e23d038f6838196fd741282127493"
    },
    {
      "line": 519,
      "relation": "positiveCorrelation",
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 140,
      "target": 155,
      "key": "fd05772ebb5ab9fa5968c43c536aaafbf2bf95215ae9d210922c4c5e3d15f9a42b2fa61f3cf139e372ce0fc88a02f643b1b5fbfb76245e0ec2670789082e8865"
    },
    {
      "line": 520,
      "relation": "positiveCorrelation",
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 140,
      "target": 142,
      "key": "be0d5961edd1e460bcf8dc2d5b3fce495884c3bf40d9d8e741e32ef8aa9991c0682bdd53805fff0b56a588b84116fbd83ae10193ee84faf0ff6142c1f286b209"
    },
    {
      "line": 545,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 140,
      "target": 44,
      "key": "834e19dbb984d9f4a03eb5f129206e86d7288a70a3402229f2fb39a6f9b5c2d32ab9c620da183a301829a923120d13a2841e78e25e28435a3656fc0a3add2b2e"
    },
    {
      "line": 583,
      "relation": "decreases",
      "evidence": "Moreover, it has been demonstrated that ChAT transcription is severely diminished in the remaining cholinergic neurons, which leads to decreased ChAT activity and progression of dementia",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 140,
      "target": 101,
      "key": "34416d5e48ce159b729edfe3b6ad732fff0c49fe494a3a3ddcfaa988fe49f8ccbb5e457ab1b96033a908e459c8c75c8aea1d8bb1dfcf1642dcbef00962f16b11"
    },
    {
      "line": 595,
      "relation": "association",
      "evidence": "Furthermore, some evidences also suggest the involvement of AChE in the pathogenesis of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 140,
      "target": 99,
      "key": "3fca74190972abb8d124e323989477a219356e05b67999ca634a9ae2827836f86d369b2fd67912e8eafc29c0843de7ffb28a2f0072fec3d482489a236034856f"
    },
    {
      "line": 647,
      "relation": "negativeCorrelation",
      "evidence": "Rivastigmine has also been used for AD treatment due to its ease of use (transdermal patch) and good tolerability by patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 140,
      "target": 28,
      "key": "96df2747746a6934eddacae5e8d27c7dbef557a1bf6cdf711eb6750876f9b2c7f45fbae0d9e504d4b0a9aaa019c0c57672844ea234d26ce22eb3d328f2418559"
    },
    {
      "line": 654,
      "relation": "negativeCorrelation",
      "evidence": "It has been demonstrated that M1 muscarinic receptors coupling to G-proteins is impaired in the neocortex of AD patients and that the extent of M1/G-protein uncoupling is related to the severity of cognitive symptoms in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        }
      },
      "source": 140,
      "target": 86,
      "key": "2921d006338a8462ab1ebb20117a056d767c9720132bf5e82c149af900ca6cd7dc9bc286b0d564ab287533c02a6207497509f237affe8fb9fd50acefeba1a5ee"
    },
    {
      "line": 576,
      "relation": "negativeCorrelation",
      "evidence": "The loss of the nucleus basalis cholinergic neurons in AD patients is severe: from about 500,000 in the healthy adult to less than 100,000 in patients displaying advanced AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 41,
      "target": 140,
      "key": "3fde9a104e55d5d687aac53a118de610efbe78cb662620b7da8e230e00b3ee37cfeb1568a54d65bae833bb5b60e4a08695d2f9a8e1edb946942fcdbd869992cb"
    },
    {
      "line": 317,
      "relation": "increases",
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 121,
      "target": 55,
      "key": "0f89e18910f3eeb966e941e655d9dad63428093f68b695b183faeb0fd7f2df89db6d264e7681e65e164f304bfbedd363bab79e6e222f8d0faf18c42c6ae6295e"
    },
    {
      "line": 318,
      "relation": "increases",
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 122,
      "target": 55,
      "key": "ae48a2aa9c9c8d76d817f78e820a7106cccdcf9ddf8a1c554ae552144fac27fd8fec299eea967cbdb8e83037e4975f21b8f836b476c45f90eca78cf781392f67"
    },
    {
      "line": 319,
      "relation": "increases",
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 123,
      "target": 55,
      "key": "e42c99da0b26084ba3d4b6af24dab075f41d17222be75c69498111a01dd23495691da378e4a07e9cd8cc5b974e54616a07af1cadd71108834bc8da270ef076e0"
    },
    {
      "line": 320,
      "relation": "increases",
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 117,
      "target": 55,
      "key": "116e30a6c2bf9482e92b23021a261f5f30187a17b2216633dac604b35f0d0b1d8694283cd0213f5725260e28c957c11186045bab13b2f8a1776ca4011b402861"
    },
    {
      "line": 321,
      "relation": "increases",
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 108,
      "target": 55,
      "key": "be608a21dcf478f3b219e6085723d05c64007ed08f765598ae7ab4019b004ff726f718ab9d8e7c074682c7d82ef3897e9e20b2350b2200a9808492cf6cf908d2"
    },
    {
      "relation": "hasComponent",
      "source": 91,
      "target": 108,
      "key": "6dc26bdd2f67a9d4e39fc6b74d80fe9e946525dc0bbd555082ff6a937962e347eab288579a461bf958247e2b39b3fb9edb0b5a020935b05852dec59a7cfb36cd"
    },
    {
      "relation": "hasComponent",
      "source": 91,
      "target": 117,
      "key": "21c91b81173c17b8bc9cc7d0094c765bbae2ae4e53c0f8c2b29200f887b167f45619d49afb5edc22a4e374d71cff476f2f37df438a60c56f74b7c8e244ef7504"
    },
    {
      "relation": "hasComponent",
      "source": 91,
      "target": 121,
      "key": "8b395a38d2734a5f2ba774096d54138c0a74fd0fc729973f32edb9ea58b6f32c302d970e165676bc1a3c585e9b4cc0ef22e724126ef2e827278737f59cca65c6"
    },
    {
      "relation": "hasComponent",
      "source": 91,
      "target": 123,
      "key": "33c4c88e2f1e127d98ebfe2f4271383d794890f607100f4bbb0f1cdb472b4a1b13261cc44456d373291c51e2ec9d0a305e78f538e351aac4a306460d45e2e671"
    },
    {
      "line": 327,
      "relation": "increases",
      "evidence": "Cholinergic nicotinic receptors expressed in muscle and ganglia are comprised of two Î± subunits plus each of the other three",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Ganglia": true,
          "Muscles": true
        }
      },
      "source": 91,
      "target": 94,
      "key": "1159ec12d390ab5abeab307e5960cd6b62770b0e580fa6715f6143fa66721254ae22837dce14c78c1bdb63755517c22e08b722778223b87115a78d9cdfc3c343"
    },
    {
      "line": 334,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 110,
      "target": 55,
      "key": "7e20aa00a0f9cd1c5bca204262cec1be91a21c03f858a3f0ee7637112e6a733a38bfd03aed226b679744612693cdd0982a9d175c5c4bce6704c8ff955b02a11d"
    },
    {
      "line": 335,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 111,
      "target": 55,
      "key": "9f4e17418591b9e8394d5d003cfcfffa9f941bf17354894bd491929da3da15dd9a4fcd00c7168cc842209be84c65d14f7f3d7ee56ffcecb96e4cfd47d2210b81"
    },
    {
      "line": 336,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 112,
      "target": 55,
      "key": "6365655c556be446785db31be7e6b5859bdd4358afbbcce1b20727a8823d190fcf99359673af3e1f4f860508961c8018d289ce780b957dc795ad0c64e46d7f9d"
    },
    {
      "line": 337,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 113,
      "target": 55,
      "key": "441e34c236916f02023f3a98ea2ffd6b9a7299559cf45758841ba6efb81d7484d43dcbe9e2881edbb4933b3808cf2bc794b85434b349d005ce7d376562a2df51"
    },
    {
      "line": 338,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 114,
      "target": 55,
      "key": "7d34b7bfd6a96abd8321630960fe40f7b20e0c90c2914cf79ea8da99671288dd41eb0cfe459f6b3ee7fabf0126c1a082fc71f381c1d9a6d5f8f75dda81c7644c"
    },
    {
      "line": 339,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 115,
      "target": 55,
      "key": "b5808aaab18561044fa95394fb2b9d5e1d8ec279a3f5848977ba67183906b4df145a5dc022516a9517badf1a3442e2cbd53dc6f66f15b62571c58f1c043e03ca"
    },
    {
      "line": 340,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 116,
      "target": 55,
      "key": "b37df8ebd8affdffb57753f39dbc0ff1b3132fab25346a44fd2aa9a1c1fb3a9cd0155f5b656c95689eebbe08b9697ba75efa0fb00e91e5b055f0488311a0e052"
    },
    {
      "line": 341,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 109,
      "target": 55,
      "key": "7e9a8f7d3354576f0e33b5d893a48aece14548e980987b04da17c4daa2672e8d02cc5c72cce70c33b1eb9d6669d1b01c8faf9e13c48004218d3102794040a22b"
    },
    {
      "line": 342,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 118,
      "target": 55,
      "key": "dfb2832f2af68f46673717c2a7e81fb0d9393bf66f099ca97036394b82d3df23d193a9e6e2d756e76af37ec1a78c87dae5a100957e44715d41ac52c215505d67"
    },
    {
      "line": 343,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 119,
      "target": 55,
      "key": "f4456605a7472367cb198b26a0e32e879b549875c3d18b7ae5d34ec5239ad60f590e99840336454cd2084de2725051d967f830d1e7653390322e7fd905d4e253"
    },
    {
      "line": 344,
      "relation": "increases",
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 120,
      "target": 55,
      "key": "42115dc7a80281950b68ebe0ef733c4f1861d2eb94d56f58375cc70c2bf867c6157fca27d54a46f470374ea661f24e85b0813951d91b9a6475cb2c488cee10d1"
    },
    {
      "line": 568,
      "relation": "association",
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 78,
      "target": 75,
      "key": "3424b8d80197a407e7d14a088d431ddf81d7539d1a185f6419e594a94b4cf27087b579d6caa3359909f7afd6289dfedbdd713dac1aff581296247d063edaac10"
    },
    {
      "line": 367,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 6,
      "target": 8,
      "key": "8f4ebb6527141747f2918150c436381ca076a31a5819ef2bfcdacbe5219ef546dc3661fdd6e238fdabcbe3150b4f368324d9c9d1cd5e5a2605a05a203441b4db"
    },
    {
      "line": 368,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 6,
      "target": 7,
      "key": "d793148cfe4efb23f7ab46db013d22742a7a8cc1989335cf88e06c3287a84d845eb4df783345e4be2a8aee510a4e86ff05b6228fa08aa08f70305d2a1075fa7a"
    },
    {
      "line": 369,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 6,
      "target": 20,
      "key": "a28586547264c55114a7fd6c698459c988571ce82e59372f2af89ffc868fd7ddf3b4a74158e6544afaac11c6aa2ee8a76d7fa63124df7f7ec2a4bfda7b0f31ab"
    },
    {
      "line": 370,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 6,
      "target": 29,
      "key": "92318cf8f5ed71441b7c922656ca4cf83801ab8810e06d3eba8553a37c7e877c61ce0bba38447c4239cb028a2fd703828c1d81a2463241aa913c55ed5e388b28"
    },
    {
      "line": 371,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 6,
      "target": 26,
      "key": "503786c42badadb5a9bc41029a3d92cff87308a737fd5fdf2ed1108d11b363692903b20accb90cc487d7c7c64dbf280320c0d5cf40a1a3788db015e25d282385"
    },
    {
      "line": 372,
      "relation": "increases",
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 6,
      "target": 14,
      "key": "2782566e51a3d72cee60024da9e8342d4ad8ae91fd29bdc46f45ba35d8aa75535ac6aa89c228aaf8fda4693690ab4a0fb60f25f501e6d1902b5f6aaeede77855"
    },
    {
      "line": 412,
      "relation": "regulates",
      "evidence": "Moreover,nicotinic receptors can also be regulated allosterically by Ca2+",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 6,
      "target": 94,
      "key": "a186553f90925c5cc564389c7ab8d6e0a375ab8dad2c679681c36ac3527aea09ee11d6e1107294a260e599dea12294a73e59141f3a8e96b575aeda153d341b9c"
    },
    {
      "line": 397,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 72,
      "target": 73,
      "key": "f2693492e132fae0a3c1c4e5a2157212b2d9ded0900ba3844e6cff8d06d9919518f90afec2d24d494eb5c56294c4e8d0b79cfd634066173a59c2296c02c054a6"
    },
    {
      "line": 398,
      "relation": "association",
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 72,
      "target": 77,
      "key": "a3ba4e92c95992096f478a383f7117c4aa09cbe15621c3cf97f01c6573c72da2b420892f26b637fa2dc791ec7c91c9d2ec938dd2439afa0dc7f117cf63a4370f"
    },
    {
      "line": 406,
      "relation": "increases",
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 96,
      "target": 95,
      "key": "72942728fed1dcfe9786d407ed86495af0fd332bec7747ae7be4b784db98388109f855a474246c5c444c6e3709f721577d4cea41af82ec8b84385193f837c7d6"
    },
    {
      "line": 409,
      "relation": "regulates",
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 95,
      "target": 94,
      "key": "475b31aa5fa305fa901657e249d764980fcb938cbad73b5f5acbf68aae596be9a196bb31c6c3dda3f5e72e116d6b572a31ed5e1d16d232a9acaba9b8bb53613a"
    },
    {
      "line": 408,
      "relation": "increases",
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 50,
      "target": 95,
      "key": "1e031e07f898b22aa128ab7c12506b0b9379441e4f49768360e98b9e4079430088745f8fa27a44653b812a8af8ad60453ff125e1e37026781dc5b9e84320fb1b"
    },
    {
      "relation": "hasComponent",
      "source": 79,
      "target": 0,
      "key": "d0a8bd534786aa309d6328c4b83efa961f4f1811a8ccd5dac3dd1bd1ab5108683d9f8561e4c7bc6dfce02b8e3dd1836d90c12c73a3770132a512143db642713e"
    },
    {
      "relation": "hasComponent",
      "source": 79,
      "target": 94,
      "key": "ddb07d2d01b72827655942f435a33cc157410c315f88f3e59f6d163d11f4e423a9d4462e87df7e588b5dc8442e1610915bca88a704a609c95ab2a800936544fd"
    },
    {
      "line": 416,
      "relation": "increases",
      "evidence": "Not only nicotine, but also DMPP (1,1-Dimethyl-4- phenylpiperazinium) and cystine can act as nicotinic receptor agonists",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 79,
      "target": 94,
      "key": "62b9394571c92be319d566c7e25917a99fe3a6678a9168eef841c3ae5df0b0fe34e3a3b49ad731ebf0c1b95c463c0b2c94e89e5ea151376b354a7dd520187156"
    },
    {
      "relation": "hasComponent",
      "source": 81,
      "target": 18,
      "key": "7aa63192d1dad3f5201d75d55ef0a7dcc916207b01b3805d17f814281ffe4596fbb50bd283d8a117f896b8367b8bb2791df2ac9f5864ec84e81a7c2474ae3497"
    },
    {
      "relation": "hasComponent",
      "source": 81,
      "target": 94,
      "key": "66ea126c89026a891d5a936644f53aebc5dc1200c59334acc593c076e0004086dc54503be46f0f97f0270d6198978b6827373cff3664cb312a4e36f7d3762f9e"
    },
    {
      "line": 417,
      "relation": "increases",
      "evidence": "Not only nicotine, but also DMPP (1,1-Dimethyl-4- phenylpiperazinium) and cystine can act as nicotinic receptor agonists",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 94,
      "key": "d880bd4cb412c6573112b97bbb2998ab4b13fb3bd6eb9c6b148a9262b3bd0076082d0069566d52ab442b699285257d4ac4efc1df9fd4437256e88c3670a316b8"
    },
    {
      "relation": "hasComponent",
      "source": 82,
      "target": 25,
      "key": "4145f82bce1562f0e44acefd4c607265879e345771c4f14d44a36db979ad42f20c8b3c569051823d83a397794b823e6040a982a25b09d87ebaac9d73a120d1bb"
    },
    {
      "relation": "hasComponent",
      "source": 82,
      "target": 94,
      "key": "3069ebcfcb2409924fd49c3ea4ee7f506d68e231cf68bdbbb328b98148d959af12e844de219b438e7355508bc6d19bcd83c8f911248cc1b3b93a140f6461ad46"
    },
    {
      "line": 418,
      "relation": "increases",
      "evidence": "Not only nicotine, but also DMPP (1,1-Dimethyl-4- phenylpiperazinium) and cystine can act as nicotinic receptor agonists",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 82,
      "target": 94,
      "key": "572b8c65d836a1eb74acd6d54d07c5565fb9ecdb177b304e474cf0ba9870be9f3825656fe2b2e799943bfebcfadd6b78e40ef4a247aecc91e9b72cb99858b74d"
    },
    {
      "line": 423,
      "relation": "decreases",
      "evidence": "Curare is the best known antagonist for nicotinic receptors, although this drug is not capable of blocking central nicotinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 31,
      "target": 94,
      "key": "94bda8808d5736e88442abf2376e50c1ecada9bb99c06d94cd49e0efa4fd9f118d03437d8411e1ed2c8aa0007905869b0a0bda1242b7509be94695316df910c7"
    },
    {
      "relation": "hasComponent",
      "source": 86,
      "target": 103,
      "key": "97aec1822463db3df8761ed1833bd9b8c631bd69133a32cf0f05edb098cfc5add0c52e90dcec211fcf0323bdc10fb7767dfb8bc4499755844cc51d760b5aff3c"
    },
    {
      "relation": "hasComponent",
      "source": 86,
      "target": 134,
      "key": "9fab2db717335943361c94021d48aea22a3ca902c3e31e7041bc9c831ac57199d581f32c9c9e9d7e2f1f58428105288eb936c6c9c8dc9559eea31cf074358fea"
    },
    {
      "line": 441,
      "relation": "increases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 86,
      "target": 98,
      "key": "c2c7d421ffed0fbfa8f0a5d495853f836c0b5a4bdc31a854e982559bf9bb3be87d641d3c5ac4286f7031777626ee1a879b0893390eafec2b33b894386e49bba5"
    },
    {
      "line": 442,
      "relation": "increases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 86,
      "target": 9,
      "key": "0549b4e5a9f0b597120a1d96744d3d0092377b29dca6def4d764260a3abde9911126f95cbdbd03e4da92fbf94c0ef34a90658585dd6236cb055e2d2b7c55666b"
    },
    {
      "line": 443,
      "relation": "decreases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 86,
      "target": 49,
      "key": "56e2c32521eff4a83ec348b241673663ddebbe244f022c87e104d05e965944f966c32c57381644649f5e2070ccfe08223a9e5c3cf3ad12d4023e150bf50b5964"
    },
    {
      "line": 483,
      "relation": "increases",
      "evidence": "On the other hand, stimulation of GÎ±q coupled muscarinic receptors generates intracellular second messengers that can facilitate N-methyl-D-aspartate (NMDA) currents",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 86,
      "target": 54,
      "key": "1356494936d6a1a8af911cb85e9a5be646212c6a09c92f1936c9dfce116a33ab41607a913e6694eeb5bfc5bbaad1e829c60611c54022e1b9ebc10a5ecdfa116b"
    },
    {
      "line": 654,
      "relation": "negativeCorrelation",
      "evidence": "It has been demonstrated that M1 muscarinic receptors coupling to G-proteins is impaired in the neocortex of AD patients and that the extent of M1/G-protein uncoupling is related to the severity of cognitive symptoms in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        }
      },
      "source": 86,
      "target": 140,
      "key": "3ca5f507a20b7ff63b9e6777882070980f0586ceaea6cff2332165ae7c5c039c62c158f79e650e3dd6982d4806807b447634b17ed7cdef6e9e3f7b6fb9fbec67"
    },
    {
      "line": 655,
      "relation": "increases",
      "evidence": "It has been demonstrated that M1 muscarinic receptors coupling to G-proteins is impaired in the neocortex of AD patients and that the extent of M1/G-protein uncoupling is related to the severity of cognitive symptoms in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        }
      },
      "source": 86,
      "target": 73,
      "key": "3208bae3bda72db91decaf76440e73fe46480b06e709e6fe7dd0e4bf82fe5d4578a619c26b7915baaf8447edeb8ec206ab224b636c69a9e7de5ec29d6637ab7d"
    },
    {
      "line": 660,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 44,
      "key": "65013de5b2e380c1ec816482f4d49cd1585df145b243e3e1730576473116eceac6240450a104b625827af63afcfb6756fc5fb1ca4bfbdd284ff6db2c27d493bd"
    },
    {
      "line": 661,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 142,
      "key": "0d698a7d0abfdaa778ffe663c10d9fed8c5de7a073acd7ac65c361721c5b203eda6297a3effd46b95dfac8111da009e42a2d165613294158f84634c7f5b866fb"
    },
    {
      "line": 662,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 125,
      "key": "79f9c68e3627a45895f8b9f72a3751b9cd45f12489325e7c53d3e5d891cf1e2e7c450a40790df6b030ae45e717dd6a8256ec2af8122fa03f3f23721cba7ad58d"
    },
    {
      "line": 663,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 5,
      "key": "f7c02317cca1268515c1fae9e39e02fd968a14016c7f10804896cb36a1eb03f5102f4bfe3ab57fcc90f867b1e7699d1253937d06a0723b0f8a9c5b6a437a9d99"
    },
    {
      "line": 668,
      "relation": "decreases",
      "evidence": "It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3Î²",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 126,
      "key": "21ef9f1ceb29b2806f5be3d649b498e4d4dc348917014b3313b5b43179902fb788e2f3712f58916199f2203ab74e0e27712d135d35a6cf40d871915ef1fca878"
    },
    {
      "line": 669,
      "relation": "increases",
      "evidence": "It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3Î²",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 97,
      "key": "89e297a2111b302bf6a324170c777d52a8181e1223077f3b996681255f4fe97c9b2c69c7bb3676677579570dcae1eb8aefb3635913fb29479483051cf2348fae"
    },
    {
      "line": 670,
      "relation": "decreases",
      "evidence": "It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3Î²",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 103,
      "target": 124,
      "key": "b98d8560a6db3d13c52ddec924fcfc6b7ca5514120f0251eca440a5cb22d9dae8f3b41fc8d6988f9e7ebf774058b6961b9942414878fdd54a863791ac37b331e"
    },
    {
      "relation": "hasComponent",
      "source": 88,
      "target": 105,
      "key": "ac70342e3d15f9d1b4368aef3db87782824b1750ee60efc56f9ee8bcb68f1a19b2c7845ac65d092dfb330ccdc04703ee88d8269726bf50c6785b0165cc341a7c"
    },
    {
      "relation": "hasComponent",
      "source": 88,
      "target": 134,
      "key": "e1bc7804311301c3c9c666ab62f00e9a2d79df7b1d6f039945648bc0ebfb972f51a53e5457223a6875b7d00b5d2650c006f85ecca5d75cb0fe0c30e5d67d99f3"
    },
    {
      "line": 444,
      "relation": "increases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 88,
      "target": 98,
      "key": "d09f327f7f3bba01f15eab826e514965e019b369a7c003b8cfba4110f33ea632fe77f151278115b2c79ab10330c5a67229bceeba89487f666c82a5f3e316783b"
    },
    {
      "line": 445,
      "relation": "increases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 88,
      "target": 9,
      "key": "28353130be8d24a53ff43fb44de309459d7fe6d7bc6dc13cc7b2ed13eef3dc5821d3cbc68f236f957840585b167cec5b438f5c045ea6354726e3b481236fd56f"
    },
    {
      "line": 446,
      "relation": "decreases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 88,
      "target": 49,
      "key": "962f82932a4aa2b9af732c4982b54d5d73c2af208f68154a47f388799d0cfdcfc16208812c1f0c6f44863bbf2e73586f8ca192c7c1126e876a6cd414782591fa"
    },
    {
      "line": 484,
      "relation": "increases",
      "evidence": "On the other hand, stimulation of GÎ±q coupled muscarinic receptors generates intracellular second messengers that can facilitate N-methyl-D-aspartate (NMDA) currents",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 88,
      "target": 54,
      "key": "ed60eedf1bb33270beae41567fda430bc2d41f195fb519dd6803257fdf36b082e551f974cdf1d52a6ccda58e0ce1b184d97a7b78761d6b52601e2d3f405f8d2f"
    },
    {
      "relation": "hasComponent",
      "source": 90,
      "target": 107,
      "key": "f404a7f80d09e9bee99af36e69524f216ad1db55bf350342bf06e9def8abfffecb286759ad144201fc1d24103633d22226911e2174a080ca86e6fe9e02c94a12"
    },
    {
      "relation": "hasComponent",
      "source": 90,
      "target": 134,
      "key": "fbf64303e151f8df377a74016d0fbd5a48822a885dfa67a7f90357d76a6c27cc3a5ebfdd784a2d6da54c52c83779de8f372e81867ec3fade23bdf61f6c413478"
    },
    {
      "line": 447,
      "relation": "increases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 90,
      "target": 98,
      "key": "93c36c207139662493c0c6678dcb84e428a02a1d5c666c60b9a94552d3b838fee3109d6ac03cdd18371296707440ca4d95999ef094e456854bf68f10d46d964d"
    },
    {
      "line": 448,
      "relation": "increases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 90,
      "target": 9,
      "key": "cc1fbbd37dba0e20ba262f697b1783f00c92cc4d8745599d7be36d08791d59032c8255871fb46f0276ab3dbc79524ac485c4b825edc3f3cb801cf5d7fd891844"
    },
    {
      "line": 449,
      "relation": "decreases",
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 90,
      "target": 49,
      "key": "9b3553eafc30ef1c779685fce07c35c78d25374dda36d6755bb6fab31938244e453b47490d42290722a874b4d895d009c0a122988d669780547e90c43a655205"
    },
    {
      "line": 485,
      "relation": "increases",
      "evidence": "On the other hand, stimulation of GÎ±q coupled muscarinic receptors generates intracellular second messengers that can facilitate N-methyl-D-aspartate (NMDA) currents",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 90,
      "target": 54,
      "key": "a09ec9aaa81b5ed3466ea27f51afe56e9fdb0062f785a8a501d262c63b85074831f1914651ff5c7c17e4e55e56bc1de27e783c4ee98b00664f65569778ac7220"
    },
    {
      "relation": "hasComponent",
      "source": 87,
      "target": 104,
      "key": "01c8dd105642a65571a874aa22d002973e2f2a9064d07c508ca2f81fad2c80d74e797638e8dc6535649aa211f480affe11cd2025332ea511d4af267fa3755649"
    },
    {
      "relation": "hasComponent",
      "source": 87,
      "target": 133,
      "key": "263fbda0c435956ca7de8ffff3ad581e15a120cfbe9978f82895aa5189e68893ab8fdf2cbf93cc98a89497725f7f34ecc166258a8a5e7df8c9e77abdf2f9cdea"
    },
    {
      "line": 456,
      "relation": "decreases",
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 87,
      "target": 92,
      "key": "28f0db5970cf501a15bd3b1496458d38cff44417df4bbf3e83ed89fc9c003cb9992e158afb2d416d6554a22200ce6b4e9168eae2f0f3f0649425ea763fdf093e"
    },
    {
      "line": 457,
      "relation": "decreases",
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 87,
      "target": 2,
      "key": "cc34c97a8a1ef5520b2f9d65fecee13ac3b1470d8303e342b0481963ded34d476765c1672096369ba50d815a81f9981db11482c009f1ebd6e0272d1dc469f402"
    },
    {
      "line": 458,
      "relation": "decreases",
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 87,
      "target": 42,
      "key": "81d6b94d033ec4996e2cfa65ac33fa02f709f90603c0a2989fab4c82b1bcd2f9e35303dacf675895e1fe2895b9d64b15c236e8839181eb73fdab52d97a349826"
    },
    {
      "line": 691,
      "relation": "decreases",
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 104,
      "target": 14,
      "key": "ec10d285d10dd0d34e566757aedf1936ce17a13a21407db6afc3dbbb82f49bf5552a92a5dc7d5cfc45e303b699592a561c02584faa847fdb37ed7a8d34303fcb"
    },
    {
      "line": 697,
      "relation": "increases",
      "evidence": "In addition, activation of M2 receptors can cause an increase in AÎ² production",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 104,
      "target": 5,
      "key": "88edf2f4373d98a531eea62d5dda99685af9bb39143b8bb5ca46d9433ebe7070360715a0b552ece377d8e26f906c6de485d8e9a51baf8d9c13579ae12008161a"
    },
    {
      "relation": "hasComponent",
      "source": 89,
      "target": 106,
      "key": "a3a9fdd8bc192b096fe065de0d8884089942becdce92c054f10e00a398d335f2fa498e685ed0af643c880ef2415fa6b6468cb7c4328966292c71ab0502b48b2d"
    },
    {
      "relation": "hasComponent",
      "source": 89,
      "target": 133,
      "key": "49d099d9d0937f5db2960557ba75ae484fd6237c92ad9fc0c374c558d87e89994911f2dc7241ffce14550cf2cb149c5bcb4fcedc76315e773f3385e3bdd1e0dd"
    },
    {
      "line": 459,
      "relation": "decreases",
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 89,
      "target": 92,
      "key": "49a13d75b41a3124c230faf5ed073598883b4d6105ddc34eff84812fcce076a2926fefa631b0892ddadf706f11d9219d5148a2bbe6cd35a38cf19fe4559b9b23"
    },
    {
      "line": 460,
      "relation": "decreases",
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 89,
      "target": 2,
      "key": "5aa2a60b5b724018b0134f0b6989ef7db6b1176213e8d08cb62c07caf4906fa1d5ac04dc5ae76db15fa2ba0f3034ce8906a98735988e4df9842c3e16acb26296"
    },
    {
      "line": 461,
      "relation": "decreases",
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 89,
      "target": 42,
      "key": "896b03272ae82f5bcaaeef53534453694ccee88d8a8d8fab494bd124741ef9f5a72993d2d38cf14724aae19678e65658df83beb4b1800345c9554b585ac533da"
    },
    {
      "relation": "hasComponent",
      "source": 80,
      "target": 12,
      "key": "9a942090a9790fab339140bdb1fd188e73f9ed5fb64a8b73f2f9a550817c4ffb8afaf93b3a359342417f8167daaff4c412d8f8c618a40f3b43806fb468f56779"
    },
    {
      "relation": "hasComponent",
      "source": 80,
      "target": 93,
      "key": "7c57ea112c88c4fe018864dfcf69a5e595fa7ef0032dd54a6f0c01108703b7eb28f860e4e2723ee8dd25a7c3cdf17d73aa0a50367954dd0d98aaf38084682241"
    },
    {
      "line": 491,
      "relation": "increases",
      "evidence": "The first selective agonist identified for muscarinic receptors was muscarine and, so far, there is no agonist available with a specific selectivity for one particular subtype of muscarinic receptor",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 80,
      "target": 93,
      "key": "7768800aa4ecb10b4aaecc93e380fb9786cb7dab0a146ffa56d0f6a756e3f019cfd48093effc14d2c279d65df1cb1fcc5de59540ac1f14eed79c565a6e60e42b"
    },
    {
      "line": 496,
      "relation": "decreases",
      "evidence": "The two best known muscarinic receptor antagonists are atropine and quinuclidinyl benzilate, which block all muscarinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 93,
      "key": "9d087c69eff331dd352ccee635f48562ba0a85f15ba10cc1293a5301ec0b9e2369c54a1fbd8a5bc8d95d2eae0a37b9934e06e6e5afa5f60fef19f4ea9b7ba118"
    },
    {
      "line": 497,
      "relation": "decreases",
      "evidence": "The two best known muscarinic receptor antagonists are atropine and quinuclidinyl benzilate, which block all muscarinic receptors",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 51,
      "target": 93,
      "key": "4f5e54143d351961239d1929eb8f8def3563597a1e35239c465e88a2c40c068f2d5f26991fbbffa0e6691da162dd23b2ad839cefa4fbad7505e5c7b514e4a3b0"
    },
    {
      "line": 503,
      "relation": "association",
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 154,
      "target": 70,
      "key": "63eeab21058e1b49be29cbffaa3a78430bfba8a7438839cf988b2430deb98214542f103864bdc9b2e24fec84b2b3ff7eb98d221254e4a49f8a33e93a8b994998"
    },
    {
      "line": 514,
      "relation": "increases",
      "evidence": "Moreover, it has been shown that blocking CA3 cholinergic receptors impairs the encoding of information and memory",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 52,
      "target": 75,
      "key": "af3c28c11dc046ebeaa8c00e1087813e6ded619e2803f9e22e74f685587d203f5b9eb47c088e803177e88f077abac11a931513add91d7a1247c3b0e9a80f7265"
    },
    {
      "line": 518,
      "relation": "positiveCorrelation",
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 151,
      "target": 140,
      "key": "3396a2dbb5b7c477621146435333b26a685b94769810e119a88ea10a096e7476b6b8b1a543e93cea7b9713460595f8610b7f2748d797fc711dca8ff6f0b76e8e"
    },
    {
      "line": 519,
      "relation": "positiveCorrelation",
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 155,
      "target": 140,
      "key": "c8df4876897d747014944c927079cea6c6b390eb8620fb5519f86201cfdca06754cf5fde9a567d8fb3ffdeb2228597cf606613caf0fd9204f7beec02a6911f0a"
    },
    {
      "line": 520,
      "relation": "positiveCorrelation",
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "source": 142,
      "target": 140,
      "key": "385a5bdca414840046642b9f421a0d922305f9cdb20b62fbcd327e987a003ac1542486397db78f5fca9eafb91e28fe3e3ca45e7779679434baab154a822af6b2"
    },
    {
      "line": 561,
      "relation": "negativeCorrelation",
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 142,
      "target": 35,
      "key": "2ab634dcbcc697456df0e2c4d4f9e4c8a5b6ca2c9617c3cdedd182e8d297aa91f7e2bc913ef57bce2c1a480b124941b265c51b127414af13212a2a842b10edd6"
    },
    {
      "line": 661,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 142,
      "target": 103,
      "key": "303234c290495a5e73ff8fd8c7250af3552cabed4e36dec50331ba19166c9c61600461ce1528572801b0763cd3bc87bf7e402dbdf40f153e3432595e1389cbb4"
    },
    {
      "line": 535,
      "relation": "decreases",
      "evidence": "Corroborating this hypothesis, it has been demonstrated that dopamine efflux is increased in the nucleus accumbens of M4 knockout mice",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        },
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 137,
      "target": 20,
      "key": "e274cc26f70c733d481eaf8be1dd777952aa5383e11d742e046a55cf9d74752e079e80df363de7447c1bf07d586ad3aefde3fc8461dd859ac9dff48507f3d36f"
    },
    {
      "line": 546,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 148,
      "target": 44,
      "key": "3fd8fbd11c54918aaffa81535d664cfccb97c8478da816eb3c065650851661bae233dfb0024342b7118e8d4e98a2eb81f6563f9ed80cc98709baf22e39715351"
    },
    {
      "line": 547,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 143,
      "target": 44,
      "key": "5472847c13c07155e1f36fcef5de5a177a0e13c7ea00704386e98089f7271424d85446e2f132175fc0f8ee7d8d174a054f2c44e7486ee11e45c5b56221b1c11f"
    },
    {
      "line": 548,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 141,
      "target": 44,
      "key": "27fa1c53294a341db24ab01e4e9706ce4c90675364b6f5c21c7543de682deab3357d27af749ed899a8b2375cf1db964692c9c4701f25c72f3f76128b92ef2a94"
    },
    {
      "line": 549,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 150,
      "target": 44,
      "key": "5816a7231a23b0110c775fa10a31f9242e3be0d0b1945aa9d4f5c4474a4a7effb598cd9eb7e22f421bf01343980fa6a7d8fce4e550f709e99196ea3048d1e293"
    },
    {
      "line": 550,
      "relation": "negativeCorrelation",
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Basal Forebrain": true
        }
      },
      "source": 147,
      "target": 44,
      "key": "39bcdc07c13ad750ff74f67d5d067c1d2ff7388e9b21ef19d5d6bc5e593ae01f10c3a77e0abfbe99c1096597f6b926b96387c5de2a57c17d2df872c04ce57ef1"
    },
    {
      "line": 554,
      "relation": "negativeCorrelation",
      "evidence": "Moreover, Huntingtonâs disease appears to be associated with decreased ChAT activity",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 144,
      "target": 101,
      "key": "916d2adfe3ff9c2da14934d7a4264992ba62b7b6692c6a200e72e5ecad2fbbf99de80f7b53ec5d8b48268a8dc445e3545492d2595c88657a5dd01af253f46bac"
    },
    {
      "line": 560,
      "relation": "association",
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 37,
      "target": 33,
      "key": "f0c98ae581e4f6bb0c70718a2a5bdf7e7ad974945ee638f00e5b674abc979ff2287a4b5703c818a014053c2b5846ab656e70997530c2511d1636b2af34b7a422"
    },
    {
      "line": 560,
      "relation": "association",
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 33,
      "target": 37,
      "key": "deba40c70a6af2288afca82041dced9ea93c374c00f459c2aeaf0a438550fc72ed2093906cf2df00c28e913c624538b0dc679946ae0e093f0c5d38c540f6c637"
    },
    {
      "line": 561,
      "relation": "negativeCorrelation",
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 35,
      "target": 142,
      "key": "dd46448ba4954932a48b53895805e69cf132af5c85574537be7252d2e298d4e31fa1f40c70790988f7716472ba83261b99cc535d4a159e371acb25cdc6d90c76"
    },
    {
      "line": 569,
      "relation": "association",
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 132,
      "target": 75,
      "key": "634f2dc27c53b20f25027ea24c17fab7c8b9fcf38c4f4e516f4b3c1d7dfb7faa56e0cb85bf5bd0d1b1fad895cb518a08d5b51ceeee44be19ec3f0e4c50e1c793"
    },
    {
      "relation": "hasComponent",
      "source": 84,
      "target": 40,
      "key": "b0e3226e03b86685b6e45c50118341a1be7ab025ec57a7b60f282a0abf6c44e0d9ecddc01be14cddd87325404421125c3359c7f4f1fba188d5217c1cce6a470f"
    },
    {
      "relation": "hasComponent",
      "source": 84,
      "target": 99,
      "key": "e8b7fbcb84a392cae8d385c4db6d1feb8e220c8711f93c267ebba69af73ac043c72493b60157e75ffd36139cb5ccee48a500ff8f2881efb679db09370cb2b8ed"
    },
    {
      "line": 599,
      "relation": "increases",
      "evidence": "A molecular modeling study showed that AChE interacts with the AÎ² peptide and promotes amyloid fibril formation",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 84,
      "target": 36,
      "key": "dca611d2a484ce664ab031991b48ec9786368536df730f119c904e3eb4f8755ba98943dbb362ec6a8e17f503980d3c2566f09dd07ce2498864d24e017642d476"
    },
    {
      "line": 605,
      "relation": "increases",
      "evidence": "In this work, kinetic analyses revealed that a structural motif in AChE (a hydrophobic sequence of 35 resides peptides) was able to promote amyloid formation and its incorporation into the growing AÎ²-fibrils",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 5,
      "target": 36,
      "key": "b4997b170cb5d0ed2e26729960218b69fe00959baf14ac2b823bff131af2e4859f7dceceb3177b30ea49ca9b443d59e591e32ad9ad98795e7a290ef8af576905"
    },
    {
      "line": 663,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 103,
      "key": "ee1f55c135d92099a0ec0910faf950207c97dcbe8dbec37522b7efc9c6e975ebc8e1f9209e168e0eaa861d7e19942401fe9ba9fa4bd349a1d171aaf177c33bc0"
    },
    {
      "line": 703,
      "relation": "regulates",
      "evidence": "However, further studies have demonstrated that nicotinic receptor activation can lead to an increase in AÎ²-mediated tau phosphorylation",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 127,
      "key": "cf59c400bbac3d4faec345393d5367df28327b7633bb637cdbcb8aeb6989f2e5db4d64ebdac8ab79d42fd648d05f086bf47a57cc663991f1b0152020de491827"
    },
    {
      "line": 614,
      "relation": "decreases",
      "evidence": "In addition, quantitative autoradiography assay revealed that choline uptake was reduced in the hippocampus of these animals and that the expression of muscarinic and nicotinic cholinergic receptors was diminished",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 136,
      "target": 17,
      "key": "54a98043d1db18d6369d8b9b0926288fc8c975e591d8d8add79225cfed2d6c4a6e2c90c635089b13fcadcabdec5f4a79a6db8f0504b8deecdd6682ca86f40244"
    },
    {
      "line": 615,
      "relation": "decreases",
      "evidence": "In addition, quantitative autoradiography assay revealed that choline uptake was reduced in the hippocampus of these animals and that the expression of muscarinic and nicotinic cholinergic receptors was diminished",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 136,
      "target": 93,
      "key": "59bd0f653a54a74fbb1ba6dca74ee67c019d92e0f8219ea6bf5f94cea24a8c0d306e179ace65b133e5c73b6949fa5f86893f356d903ea8a0a010530cb23ed29e"
    },
    {
      "line": 616,
      "relation": "decreases",
      "evidence": "In addition, quantitative autoradiography assay revealed that choline uptake was reduced in the hippocampus of these animals and that the expression of muscarinic and nicotinic cholinergic receptors was diminished",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 136,
      "target": 94,
      "key": "7fa89e94eb87e7f2268fbd0e3eda9b650a13acdb134b0469dd9ecd07b569081c4b77c33053daae89c8c3be4c4c7cd172a0960cab40f3dfa798f0359fa3d03539"
    },
    {
      "relation": "hasVariant",
      "source": 135,
      "target": 136,
      "key": "92ab82e51e25478c59ada31ae634e8dc5fa97aac5fcf141761af663f78d6c7606531d40ca010d5a522e81d0df6a8e8643c6649a235381911a8d0ef877041dcfe"
    },
    {
      "line": 627,
      "relation": "increases",
      "evidence": "Cholinesterase inhibitors can increase ACh levels in the synaptic cleft and partially ameliorate cognitive symptoms, enhance quality of life and diminish caregiver burden for patients with mild to severe AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 45,
      "target": 14,
      "key": "453feafd07cd36fe733d16930667558dda84286534133460fec5da2028ad98844f85ea73cee14c85ac9abe472411cc1a05395a706a3b57d01b1bb4cf573e16b0"
    },
    {
      "line": 628,
      "relation": "increases",
      "evidence": "Cholinesterase inhibitors can increase ACh levels in the synaptic cleft and partially ameliorate cognitive symptoms, enhance quality of life and diminish caregiver burden for patients with mild to severe AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 45,
      "target": 73,
      "key": "d84795d44f5177f183ff973056c4d5a460d3471ee52ac8781810687e9c571f79fc71c2400ecd8c4313d8aab6a505de1f37f4e7682e3cb9dce3c1ffb5ec507626"
    },
    {
      "line": 634,
      "relation": "increases",
      "evidence": "It has been demonstrated that treatment with donepezil is associated with significant cognitive and functional benefits over the course of 12 months in patients with moderate to severe AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 19,
      "target": 73,
      "key": "93fa6d94e55cc6427880347ca458e21980d19e3f67d519f711ea213da49da1e67a7f59798ca149b3a048a85b4397c4227f5dfd1dd6fbafc2a6a19e7ec5175082"
    },
    {
      "line": 641,
      "relation": "decreases",
      "evidence": "In a double-blind study designed to assess patients survival with mild to moderately severe AD, the long-term treatment (2 years) with galantamine significantly reduced mortality and cognition decline, besides improving daily live activities in mild to moderate AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 22,
      "target": 153,
      "key": "56a54e2804970dd274607ab54db136493a211baacf38e0c98869cbad4414d88f86f556165ac6b0bea73776724cab733088c4c066844c98eeb7059f453779a361"
    },
    {
      "line": 642,
      "relation": "increases",
      "evidence": "In a double-blind study designed to assess patients survival with mild to moderately severe AD, the long-term treatment (2 years) with galantamine significantly reduced mortality and cognition decline, besides improving daily live activities in mild to moderate AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 22,
      "target": 73,
      "key": "3c9e66911ca43938cd65b007dff1b88432220ca186debaa511c70392a3463b985edea297749bc65ce2be13894cda79c8cfb012167362e76a0da66b07388acc5a"
    },
    {
      "line": 647,
      "relation": "negativeCorrelation",
      "evidence": "Rivastigmine has also been used for AD treatment due to its ease of use (transdermal patch) and good tolerability by patients",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 28,
      "target": 140,
      "key": "62ae10d9ce1e6c2ea20b30ff72c55031db8aad02a152c8bb6ef75ce9d71c02c22deb769fb94b44388c6f851d761c93aecd142f368c4c92d59db953f4549a69f4"
    },
    {
      "line": 662,
      "relation": "association",
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 125,
      "target": 103,
      "key": "1e4acfd8a5460eeec91f4d75f151774e2b0367012824b45b0171b44676f829210b815a8f07904e326a4c664feffc07765854420a6dccf50173354d80d2c54760"
    },
    {
      "relation": "hasVariant",
      "source": 125,
      "target": 126,
      "key": "9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2"
    },
    {
      "relation": "hasVariant",
      "source": 125,
      "target": 128,
      "key": "1f9bd7c2867036707fe963649511c37811b9c55d8f86d32aaf19a2b9ae43692126867debd9355b90aee88e793e854340f6276fe41c9492d1abb3c766f366e2e5"
    },
    {
      "relation": "hasVariant",
      "source": 125,
      "target": 127,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    },
    {
      "line": 676,
      "relation": "increases",
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 57,
      "target": 103,
      "key": "20a5f102e1aeb46a749e279efe638bbb00c7b2de66e5da1f544a1894b372293a92082aed32de47188c59d405e69270e4de47a81c2103ea4c6909a1b6b28ed0e1"
    },
    {
      "line": 677,
      "relation": "increases",
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        }
      },
      "source": 57,
      "target": 73,
      "key": "85b243b5d5e3121551333aa080f296485fff65072da64cbc08950b4619bff86dd811097dfe25404d1670cc1ab9658f978b282d4f37090693e87c05d71a6b5299"
    },
    {
      "line": 678,
      "relation": "decreases",
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        }
      },
      "source": 57,
      "target": 4,
      "key": "9a675c4d31d862536b1dce92c901229b11729f126dadde1c93dadcb641346edb12adc36ca646f954f79bcfdbd02a352ed075ffde92c8b4327cb28d0b88a6106a"
    },
    {
      "line": 679,
      "relation": "decreases",
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        }
      },
      "source": 57,
      "target": 128,
      "key": "8b62d988af75e908d997373273aa193e8ab5e05db0bcd83579ff13712810d8a97f5b4c903069b7b79ec7882823e28551eb68569430d94427a09d0e1fdbb06997"
    },
    {
      "line": 684,
      "relation": "increases",
      "evidence": "Moreover, AF267B treatment leads to an increase in alpha secretase, which is an enzyme that can prevent the production of AÎ² peptide",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 57,
      "target": 39,
      "key": "a6e2d14a898afc73dcdba61ab9002aaaf9e74a2e4c5d053437a8644d13acf8ba6ff34ad80ad70722b9aca017a5ded6b6ca18f32787ad5e341922a66fc21ee2ab"
    },
    {
      "line": 685,
      "relation": "decreases",
      "evidence": "Moreover, AF267B treatment leads to an increase in alpha secretase, which is an enzyme that can prevent the production of AÎ² peptide",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 39,
      "target": 40,
      "key": "5e1c86b121dc9766cfe2302fd36e19478553b4769b0474ebcd32a8810f75caddd6e1124bc0343bce67c9dd919930e83a8f6fb807234143c863785fc867aeffac"
    },
    {
      "line": 690,
      "relation": "increases",
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          }
        }
      },
      "source": 59,
      "target": 14,
      "key": "90bc0a3d9172135e1773c9bc1e31c096c673500d39cfb5623459ad9462e21e45725f45b861d41e543111d73dc4337bc8cc7b81c8d4e92eef903f5326828b8a47"
    },
    {
      "line": 692,
      "relation": "increases",
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 59,
      "target": 103,
      "key": "c0b8089791d9c41ff9a8ff5a252847c13e74441e9ca55995e0cef34a603ee520bab599a850a8285994ce259a8fad387af436bc82dd9f3b20119ea27f73d9d8bf"
    },
    {
      "line": 693,
      "relation": "increases",
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 59,
      "target": 55,
      "key": "5505f52f2aa972bc589024235e62d3192858217a43d82593f9fa2d48ca22f91639489c3ca76161c56dc6c5406a0b96d4feb958a89cf38dbcf262406534f06666"
    },
    {
      "line": 694,
      "relation": "increases",
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 59,
      "target": 73,
      "key": "8097037a4ca3491d6ce4427f9cecdb91e1fe35c42c4cd0d6dc51555954f71a0646856c2f2b15ff464d192b6d1d8d459797979b5bead36ff0c40a8c11bb2f7c91"
    },
    {
      "line": 711,
      "relation": "increases",
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 73,
      "key": "8696d1becbc5307b910502e581501ad9de863cd158a37ebbe55236dd1132e1105feae76293f6af52d560da44952e06ea4a0aa3b0aaeadb604e1c4719b92f18e6"
    },
    {
      "line": 712,
      "relation": "increases",
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 75,
      "key": "650998ee6af66c5302005dee41b0644d62ac68d11525ec166ea0a3dc758561c0535379f60a5ebb8e6fac06dd0665dda6faa1ff91b97887ca3fe61200d23d84eb"
    },
    {
      "line": 713,
      "relation": "decreases",
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 145,
      "key": "73db74feea35b78c05a386d865780207f2fb57f8d2f9be22206edf78230951232ca706b0d58d61dd638262207781048098bb866deb61b82914b380322f59de3d"
    },
    {
      "line": 714,
      "relation": "decreases",
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 149,
      "key": "f7335d7157418cb697eacfcc8e97930733f46b442c3a985242e9eb740ee8484e6fce7e1edd2a1ced314853c063bef115eee80e673959cf6c2b02139eda823ea4"
    },
    {
      "line": 715,
      "relation": "decreases",
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 156,
      "key": "4a3ef3af0a2b45308b2f281b46185f014398dcf9646bbfb69ce010e8b44ed9f974d3e3580a317d944c2327ec3c921dd7e2a21bdf592a3c68122072605367f3d8"
    },
    {
      "line": 724,
      "relation": "increases",
      "evidence": "For example, it has been shown that the benzyl quinolone carboxylic acid (BQCA), which is an M1-selective allosteric agonist, is effective in increasing spontaneous excitatory postsynaptic currents in the medial prefrontal cortex (mPFC) pyramidal cells and improving memory in a transgenic mouse model of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true
        }
      },
      "source": 58,
      "target": 64,
      "key": "1618c84c80af4df479bcb366fd291aedeff35229047f59a2561a50d86c4d76de4184e9efbd137d98abdcbef9efe81f19bdd0cd81b56f6137f949fc23115a17f6"
    },
    {
      "line": 725,
      "relation": "increases",
      "evidence": "For example, it has been shown that the benzyl quinolone carboxylic acid (BQCA), which is an M1-selective allosteric agonist, is effective in increasing spontaneous excitatory postsynaptic currents in the medial prefrontal cortex (mPFC) pyramidal cells and improving memory in a transgenic mouse model of AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true
        }
      },
      "source": 58,
      "target": 75,
      "key": "8ad30f6fdb5f9bb04e6c8124d5f3cf9d9729d18504a75d08a02a4484449d51d25784fe4a38281c1cfa3092f73b9776fee4af36ad4806af7ef72d55f348a24626"
    },
    {
      "relation": "hasComponent",
      "source": 85,
      "target": 100,
      "key": "c673d43cb9c0a13c104bd8b10da30edf48ad994aee93e9f4e229224e903f23ab144345247dd1989280be6cacf5667530fa1d419f875574abb870e45c60707a27"
    },
    {
      "line": 731,
      "relation": "increases",
      "evidence": "In fact, it has been shown that APP interacts with CHT1 proteins increasing their endocytosis from the cell surface [258] and that mice that display disruption of CHT1 gene expression exhibit symptoms related to ACh deficit",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "cell surface"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 85,
      "target": 100,
      "key": "7cc358bdca5253c04c3bc5994b5e2d65bb8ccbf7b78bd8308310332e0c1c7c065fa1eecbcf7dcb64120bd28caba5c249f554dd52ab5df90ec88f95ddb8b3e42e"
    },
    {
      "relation": "hasComponent",
      "source": 85,
      "target": 131,
      "key": "d470464ad7ba995b8980ad390d32f3341c1933c0d30fe5b8e758473813fac90f712f0bd04f039444a831ce7c47b8ee87b42b2012f641d1450e1bb906059d67e9"
    },
    {
      "line": 735,
      "relation": "decreases",
      "evidence": "In fact, memantine is able to reduce the excitotoxicity in AD",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 23,
      "target": 38,
      "key": "184c398a0962bf30dec8076f6d89c1c3fb5e7d41d747dcf99f2883049437b93735f2f28f0557ac9657892fed0394bea802eadfd89660e73c63c92a92f5f427fd"
    },
    {
      "line": 741,
      "relation": "increases",
      "evidence": "Furthermore, it has also been proposed that the nerve growth factor (NGF) has the potential to preserve cholinergic neurons",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 48,
      "target": 44,
      "key": "0d3caf9ebe51d6cec42c63590be49586aff3ab72be0cf2409e6019717794cfdb5bac76a0b6423d2a17da177e53d4437b11f57fb4e00187bd7fd8db6d414fdca9"
    },
    {
      "line": 746,
      "relation": "increases",
      "evidence": "Moreover, previous studies have shown that treatment with NGF can counteract cholinergic atrophy and memory deficits in aged rats",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 48,
      "target": 44,
      "key": "ec503016f6ddf0475da920bad2ef630cea747e9ace61e66d9a98fc6b49ba980d38a07a87495da809c3b95c8398a739945b42cba3864b5b370db826be9e1d11db"
    },
    {
      "line": 747,
      "relation": "increases",
      "evidence": "Moreover, previous studies have shown that treatment with NGF can counteract cholinergic atrophy and memory deficits in aged rats",
      "citation": {
        "type": "PubMed",
        "reference": "26813123",
        "name": "Current neuropharmacology",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "volume": "14",
        "pages": "101-15",
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ]
      },
      "source": 48,
      "target": 75,
      "key": "a686dd1934333d02663406f34d6914d6137da4689d22c81d62053da7fbb1febc3c0079e8aa154e53f4434e52937a9cc034200a105f1c900351ca5969d7216c7d"
    }
  ]
}